CA3021752A1 - Nanoparticulate ivacaftor formulations - Google Patents
Nanoparticulate ivacaftor formulations Download PDFInfo
- Publication number
- CA3021752A1 CA3021752A1 CA3021752A CA3021752A CA3021752A1 CA 3021752 A1 CA3021752 A1 CA 3021752A1 CA 3021752 A CA3021752 A CA 3021752A CA 3021752 A CA3021752 A CA 3021752A CA 3021752 A1 CA3021752 A1 CA 3021752A1
- Authority
- CA
- Canada
- Prior art keywords
- ivacaftor
- nanoparticulate
- composition
- less
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 title claims abstract description 288
- 229960004508 ivacaftor Drugs 0.000 title claims abstract description 269
- 239000000203 mixture Substances 0.000 title claims abstract description 243
- 238000009472 formulation Methods 0.000 title claims description 80
- 239000002245 particle Substances 0.000 claims abstract description 104
- 239000003381 stabilizer Substances 0.000 claims abstract description 103
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- -1 acetate - polyethylene Chemical group 0.000 claims description 62
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 24
- 239000003826 tablet Substances 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 22
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 21
- 239000006185 dispersion Substances 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 18
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 18
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229960000878 docusate sodium Drugs 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 10
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 10
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229940014259 gelatin Drugs 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 229920001983 poloxamer Polymers 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 9
- 239000000443 aerosol Substances 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 9
- 235000010980 cellulose Nutrition 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 125000005456 glyceride group Chemical group 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 229960003943 hypromellose Drugs 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 235000021317 phosphate Nutrition 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 102000016943 Muramidase Human genes 0.000 claims description 5
- 108010014251 Muramidase Proteins 0.000 claims description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229940050528 albumin Drugs 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 5
- 235000013539 calcium stearate Nutrition 0.000 claims description 5
- 239000008116 calcium stearate Substances 0.000 claims description 5
- 229940078456 calcium stearate Drugs 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 5
- 238000013265 extended release Methods 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 229920000578 graft copolymer Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 239000004325 lysozyme Substances 0.000 claims description 5
- 235000010335 lysozyme Nutrition 0.000 claims description 5
- 229960000274 lysozyme Drugs 0.000 claims description 5
- 229960003511 macrogol Drugs 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 229960002900 methylcellulose Drugs 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229920001987 poloxamine Polymers 0.000 claims description 5
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 5
- 229940068917 polyethylene glycols Drugs 0.000 claims description 5
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 5
- 239000011118 polyvinyl acetate Substances 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 230000000541 pulsatile effect Effects 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 5
- 229920001664 tyloxapol Polymers 0.000 claims description 5
- 229960004224 tyloxapol Drugs 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 4
- 235000006491 Acacia senegal Nutrition 0.000 claims description 4
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 150000005215 alkyl ethers Chemical class 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 229920001531 copovidone Polymers 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000008387 emulsifying waxe Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 4
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 4
- 229940072106 hydroxystearate Drugs 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 4
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 claims 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 63
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 29
- 239000003814 drug Substances 0.000 description 31
- 229940079593 drug Drugs 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000003801 milling Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 17
- 239000006070 nanosuspension Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 229940005405 kalydeco Drugs 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 239000013543 active substance Substances 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 239000002105 nanoparticle Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000002612 dispersion medium Substances 0.000 description 9
- 238000000227 grinding Methods 0.000 description 9
- 239000007909 solid dosage form Substances 0.000 description 9
- 208000025678 Ciliary Motility disease Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 201000010064 diabetes insipidus Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000007962 solid dispersion Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229920003072 Plasdone™ povidone Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229960003742 phenol Drugs 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010067265 Heterotaxia Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000015439 Lysosomal storage disease Diseases 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 208000031733 Situs inversus totalis Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 4
- 150000003868 ammonium compounds Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229940107161 cholesterol Drugs 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 208000008797 situs inversus Diseases 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000010922 spray-dried dispersion Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229960004274 stearic acid Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 206010002961 Aplasia Diseases 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 102000004321 Atrophin-1 Human genes 0.000 description 2
- 108090000806 Atrophin-1 Proteins 0.000 description 2
- 208000012904 Bartter disease Diseases 0.000 description 2
- 208000010062 Bartter syndrome Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 2
- 208000031976 Channelopathies Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010062264 Congenital hyperthyroidism Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
- 208000024940 Dent disease Diseases 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 2
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 2
- 208000019683 Gorham-Stout disease Diseases 0.000 description 2
- 229920003115 HPC-SL Polymers 0.000 description 2
- 206010019860 Hereditary angioedema Diseases 0.000 description 2
- 208000033981 Hereditary haemochromatosis Diseases 0.000 description 2
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 2
- 201000000101 Hyperekplexia Diseases 0.000 description 2
- 206010058271 Hyperexplexia Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 2
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- 208000003892 Kartagener syndrome Diseases 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008955 Mucolipidoses Diseases 0.000 description 2
- 206010072928 Mucolipidosis type II Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 208000025237 Polyendocrinopathy Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
- 201000005660 Protein C Deficiency Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920002359 Tetronic® Polymers 0.000 description 2
- 208000035954 Thomsen and Becker disease Diseases 0.000 description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 208000004622 abetalipoproteinemia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical class Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000009246 food effect Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 229940020017 ivacaftor 50 mg Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 208000000638 myeloperoxidase deficiency Diseases 0.000 description 2
- 230000002988 nephrogenic effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000020978 protein processing Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical class [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- PKPZZAVJXDZHDW-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;hydrochloride Chemical compound Cl.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO PKPZZAVJXDZHDW-LJTMIZJLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- AFLDFEASYWNJGX-UHFFFAOYSA-N 1-(4-iodophenyl)-n-propan-2-ylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)NC(C)CC1=CC=C(I)C=C1 AFLDFEASYWNJGX-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- DBRHJJQHHSOXCQ-UHFFFAOYSA-N 2,2-dihydroxyethyl(methyl)azanium;chloride Chemical compound [Cl-].C[NH2+]CC(O)O DBRHJJQHHSOXCQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- YJHSJERLYWNLQL-UHFFFAOYSA-N 2-hydroxyethyl(dimethyl)azanium;chloride Chemical compound Cl.CN(C)CCO YJHSJERLYWNLQL-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000003926 acrylamides Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 150000001279 adipic acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- TWJVNKMWXNTSAP-UHFFFAOYSA-N azanium;hydroxide;hydrochloride Chemical compound [NH4+].O.[Cl-] TWJVNKMWXNTSAP-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- 229940075506 behentrimonium chloride Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- UUZYBYIOAZTMGC-UHFFFAOYSA-M benzyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CC1=CC=CC=C1 UUZYBYIOAZTMGC-UHFFFAOYSA-M 0.000 description 1
- YYMVPVZYUYQSJE-UHFFFAOYSA-N benzyl-[2-(2,6-dimethylanilino)-2-oxoethyl]-diethylazanium;benzoate;hydrate Chemical compound O.[O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C YYMVPVZYUYQSJE-UHFFFAOYSA-N 0.000 description 1
- IBNQLYMPUGQNLN-UHFFFAOYSA-M benzyl-[2-(4-dodecanoylphenoxy)ethyl]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(C(=O)CCCCCCCCCCC)=CC=C1OCC[N+](C)(C)CC1=CC=CC=C1 IBNQLYMPUGQNLN-UHFFFAOYSA-M 0.000 description 1
- BCOZLGOHQFNXBI-UHFFFAOYSA-M benzyl-bis(2-chloroethyl)-ethylazanium;bromide Chemical compound [Br-].ClCC[N+](CC)(CCCl)CC1=CC=CC=C1 BCOZLGOHQFNXBI-UHFFFAOYSA-M 0.000 description 1
- WMLFGKCFDKMAKB-UHFFFAOYSA-M benzyl-diethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](CC)(CC)CC1=CC=CC=C1 WMLFGKCFDKMAKB-UHFFFAOYSA-M 0.000 description 1
- RWUKNUAHIRIZJG-AFEZEDKISA-M benzyl-dimethyl-[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC1=CC=CC=C1 RWUKNUAHIRIZJG-AFEZEDKISA-M 0.000 description 1
- WNBGYVXHFTYOBY-UHFFFAOYSA-N benzyl-dimethyl-tetradecylazanium Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 WNBGYVXHFTYOBY-UHFFFAOYSA-N 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- BWNMWDJZWBEKKJ-UHFFFAOYSA-M benzyl-docosyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 BWNMWDJZWBEKKJ-UHFFFAOYSA-M 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000008372 bubblegum flavor Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CDJGWBCMWHSUHR-UHFFFAOYSA-M decyl(triethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](CC)(CC)CC CDJGWBCMWHSUHR-UHFFFAOYSA-M 0.000 description 1
- RLGGVUPWOJOQHP-UHFFFAOYSA-M decyl-(2-hydroxyethyl)-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCO RLGGVUPWOJOQHP-UHFFFAOYSA-M 0.000 description 1
- 229960001610 denatonium benzoate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229940073551 distearyldimonium chloride Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HBRNMIYLJIXXEE-UHFFFAOYSA-N dodecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCN HBRNMIYLJIXXEE-UHFFFAOYSA-N 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005367 electrostatic precipitation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- ULBMBQLPJXAYAG-UHFFFAOYSA-N ethyl-dimethyl-(1-phenyltridecyl)azanium Chemical compound CCCCCCCCCCCCC([N+](C)(C)CC)C1=CC=CC=C1 ULBMBQLPJXAYAG-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- DWURWFGXBSEKLI-UHFFFAOYSA-M heptyl-dimethyl-(2-oxo-1,2-diphenylethyl)azanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C([N+](C)(C)CCCCCCC)C(=O)C1=CC=CC=C1 DWURWFGXBSEKLI-UHFFFAOYSA-M 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229950007325 lauralkonium chloride Drugs 0.000 description 1
- 229940116263 laurtrimonium chloride Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- ISWNAMNOYHCTSB-UHFFFAOYSA-N methanamine;hydrobromide Chemical compound [Br-].[NH3+]C ISWNAMNOYHCTSB-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- VXBSKVAMQMBCCA-UHFFFAOYSA-M methyl sulfate;trimethyl(tetradecyl)azanium Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCC[N+](C)(C)C VXBSKVAMQMBCCA-UHFFFAOYSA-M 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940094510 myristalkonium chloride Drugs 0.000 description 1
- HICYUNOFRYFIMG-UHFFFAOYSA-N n,n-dimethyl-1-naphthalen-1-ylmethanamine;hydrochloride Chemical compound [Cl-].C1=CC=C2C(C[NH+](C)C)=CC=CC2=C1 HICYUNOFRYFIMG-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- UMWKZHPREXJQGR-XOSAIJSUSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]decanamide Chemical compound CCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UMWKZHPREXJQGR-XOSAIJSUSA-N 0.000 description 1
- VHYYJWLKCODCNM-OIMNJJJWSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]heptanamide Chemical compound CCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO VHYYJWLKCODCNM-OIMNJJJWSA-N 0.000 description 1
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- UPHWVVKYDQHTCF-UHFFFAOYSA-N octadecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCCN UPHWVVKYDQHTCF-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 150000003018 phosphorus compounds Chemical group 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940057981 stearalkonium chloride Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- FAGMGMRSURYROS-UHFFFAOYSA-M trihexadecyl(methyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(CCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCC FAGMGMRSURYROS-UHFFFAOYSA-M 0.000 description 1
- HVLUSYMLLVVXGI-USGGBSEESA-M trimethyl-[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)C HVLUSYMLLVVXGI-USGGBSEESA-M 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to nanoparticulate compositions of ivacaftor or a pharmaceutically acceptable salt thereof, and methods of making and using such compositions. The compositions comprise ivacaftor particles having an effective average particle size of less than about 2000 nm. The invention also comprises at least one surface stabilizer and optionally one or more pharmaceutically acceptable excipients.
Description
NANOPARTICULATE IVACAFTOR FORMULATIONS
FIELD OF THE INVENTION
The present invention relates to nanoparticulate compositions of ivacaftor or a pharmaceutically acceptable salt thereof, and methods of making and using such compositions.
The compositions comprise ivacaftor particles having an effective average particle size of less than about 2000 nm.
BACKGROUND OF THE INVENTION
Ivacaftor is a potent and selective CFTR potentiator approved for the treatment of cystic fibrosis with a certain mutations in CFTR gene. It is approved as tablet and granules for oral administration under the brand name KALYDECO . Ivacaftor is chemically known as N-(2,4-di -tert-b uty1-5-hydroxypheny1)-1,4-dihydro-4-oxoquinoline-3 -carboxami de and has the following structural formula:
OH \ , [
-N-' U.S. Patent No. 7,495,103 discloses modulators of ATP-binding cassette transporters such as ivacaftor and also discloses methods of treating CFTR transporter mediated diseases using such modulators.
U.S. Patent No. 7,553,855 discloses a pharmaceutical composition comprising: N-(5-hydroxy-24-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Ivacaftor), PEG 400, and PVP K30.
U.S. Patent No. 8,410,274 discloses solid dispersion of amorphous N42,4-bis(1,1-di methyl ethyl)-5-hydroxyphenyl] -1,4-dihydro-4-oxoquinol i ne-3 -carboxami de, pharmaceutical compositions thereof and methods therewith.
U.S. Patent No. 8,163,772 discloses solid forms of ivacaftor in form of co-forms with 2-methyl butyric acid, propylene glycol, PEG400.KOAc, lactic acid, isobutyric acid, propionic acid, ethanol, 2-propanol, water, besylate, hemibesylate, and besylate monohydrate.
U.S. Patent No. 8,883,206 discloses a pharmaceutical composition of ivacaftor in form of solid dispersion with HPMCAS along with other excipients U.S. Patent Publication No. 2015/0010628 discloses a pharmaceutical composition comprising a solid dispersion of amorphous or substantially amorphous ivacaftor, a filler, a sweetener, a disintegrant, a glidant and a lubricant, and optionally a wetting agent.
U.S. Patent No. 8,471,029 discloses crystalline form C of N42,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihy dro-4-oxo quinol ine-3 -carboxami de.
US Patent No. 8,674,108 discloses crystalline solvates of ivacaftor, which are designated as Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form 0, Form P, Form Q, Form R, Form S, Form T, Form W and hydrate B and their preparation.
Ivacaftor is a white to off-white powder. It is freely soluble in methylethyl ketone/water mixture, soluble in 2-methyl tetrahydrofuran and PEG 400, slightly soluble in methanol, acetone and ethanol and practically insoluble in water (<0.05 microgram/mL) and buffers with pH 1.0 ¨7ØIvacaftor has been isolated in two physical forms, an amorphous form and a crystalline form.
Various crystalline polymorphic forms are known and Form C is the most thermodynamically stable form. The absorption of ivacaftor in mouse, rats, rabbits and dogs is rapid, following oral administration of aqueous suspensions of the amorphous form, and bioavailability ranged from 30 to 100%. At the same time the crystalline form in suspension had a low oral bioavailability.
Due to low solubility and low bioavailability of crystalline form of ivacaftor, the marketed KALYDECO tablet is prepared in two stages¨ manufacture of spray dispersion and tabletting.
The spray-dried dispersion (SDD) is manufactured using solvent based spray-drying followed by secondary drying to remove residual solvents. In the second stage, the amorphous SDD is blended with additional excipients, compressed into a core tablet, film-coated and printed to form the final drug product. Due to ivacaftor being insoluble in water, it needs to be spray-dried with excipients to produce an amorphous form of the active substance, which circumvents the
FIELD OF THE INVENTION
The present invention relates to nanoparticulate compositions of ivacaftor or a pharmaceutically acceptable salt thereof, and methods of making and using such compositions.
The compositions comprise ivacaftor particles having an effective average particle size of less than about 2000 nm.
BACKGROUND OF THE INVENTION
Ivacaftor is a potent and selective CFTR potentiator approved for the treatment of cystic fibrosis with a certain mutations in CFTR gene. It is approved as tablet and granules for oral administration under the brand name KALYDECO . Ivacaftor is chemically known as N-(2,4-di -tert-b uty1-5-hydroxypheny1)-1,4-dihydro-4-oxoquinoline-3 -carboxami de and has the following structural formula:
OH \ , [
-N-' U.S. Patent No. 7,495,103 discloses modulators of ATP-binding cassette transporters such as ivacaftor and also discloses methods of treating CFTR transporter mediated diseases using such modulators.
U.S. Patent No. 7,553,855 discloses a pharmaceutical composition comprising: N-(5-hydroxy-24-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Ivacaftor), PEG 400, and PVP K30.
U.S. Patent No. 8,410,274 discloses solid dispersion of amorphous N42,4-bis(1,1-di methyl ethyl)-5-hydroxyphenyl] -1,4-dihydro-4-oxoquinol i ne-3 -carboxami de, pharmaceutical compositions thereof and methods therewith.
U.S. Patent No. 8,163,772 discloses solid forms of ivacaftor in form of co-forms with 2-methyl butyric acid, propylene glycol, PEG400.KOAc, lactic acid, isobutyric acid, propionic acid, ethanol, 2-propanol, water, besylate, hemibesylate, and besylate monohydrate.
U.S. Patent No. 8,883,206 discloses a pharmaceutical composition of ivacaftor in form of solid dispersion with HPMCAS along with other excipients U.S. Patent Publication No. 2015/0010628 discloses a pharmaceutical composition comprising a solid dispersion of amorphous or substantially amorphous ivacaftor, a filler, a sweetener, a disintegrant, a glidant and a lubricant, and optionally a wetting agent.
U.S. Patent No. 8,471,029 discloses crystalline form C of N42,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihy dro-4-oxo quinol ine-3 -carboxami de.
US Patent No. 8,674,108 discloses crystalline solvates of ivacaftor, which are designated as Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form 0, Form P, Form Q, Form R, Form S, Form T, Form W and hydrate B and their preparation.
Ivacaftor is a white to off-white powder. It is freely soluble in methylethyl ketone/water mixture, soluble in 2-methyl tetrahydrofuran and PEG 400, slightly soluble in methanol, acetone and ethanol and practically insoluble in water (<0.05 microgram/mL) and buffers with pH 1.0 ¨7ØIvacaftor has been isolated in two physical forms, an amorphous form and a crystalline form.
Various crystalline polymorphic forms are known and Form C is the most thermodynamically stable form. The absorption of ivacaftor in mouse, rats, rabbits and dogs is rapid, following oral administration of aqueous suspensions of the amorphous form, and bioavailability ranged from 30 to 100%. At the same time the crystalline form in suspension had a low oral bioavailability.
Due to low solubility and low bioavailability of crystalline form of ivacaftor, the marketed KALYDECO tablet is prepared in two stages¨ manufacture of spray dispersion and tabletting.
The spray-dried dispersion (SDD) is manufactured using solvent based spray-drying followed by secondary drying to remove residual solvents. In the second stage, the amorphous SDD is blended with additional excipients, compressed into a core tablet, film-coated and printed to form the final drug product. Due to ivacaftor being insoluble in water, it needs to be spray-dried with excipients to produce an amorphous form of the active substance, which circumvents the
2 solubility limited bioavailability issues of the crystalline form and hence is better absorbed. The KALYDECO granules are pre-compressed amorphous SDD blended with other excipients.
The exposure of ivacaftor increased approximately 2.5-to 4-fold when given with food that contains fat. Therefore, KALYDECO tablet is administered with fat-containing food. Examples of fat-containing foods include eggs, butter, peanut butter, cheese pizza, whole-milk dairy products (such as whole milk, cheese, and yogurt), etc. KALYDECO granules (2 x 75 mg) had similar bioavailability as the 150 mg tablet when given with fat-containing food in adult subjects.
The effect of food on ivacaftor absorption is similar for KALYDECO granules and the 150 mg tablet formulation.
Clinical study during KALYDECO* product development shows clear food affect.
After oral administration of a single 150 mg dose to healthy volunteers in the fasted state, the mean (SD) for AUC0,õ and Cmax were 3620 (1840) ng*hr/mL and 218 (110) ng/mL, respectively. In the same study, oral administration of a single 150 mg dose in the fed state led to a substantial increase in exposure: AUC0,õ was 10600 (5260) ng*hr/mL and Cmax was 768 (233) ng/mL. The exposure of ivacaftor increased approximately 2- to 4-fold when given with food containing fat.
Therefore, KALYDECO is administered with fat-containing food. There is a clear effect of concomitant food intake on the speed and magnitude of absorption of ivacaftor.
In healthy volunteers high fat breakfast increased Cmax and AUC of 150 mg tablet formulation by an order of magnitude around 2- to 4 and delayed Tmax from 3 to 5 hours. A consistent effect was observed in patients with CF and pancreatic insufficiency in whom ivacaftor 275 mg oral solution was given. In this later case a standard CF meal (which contains up to 200% of the fat content of a standard meal) was compared with a fasted state. The impact of food on the PK of ivacaftor may have implications in clinical practice. Clinical studies were conducted advising patients to take ivacaftor with food containing fat. A recommendation that ivacaftor to be taken with food or shortly after a meal is included in the labeling information issued by the FDA and EMEA in respect of the KALYDECO . If a patient does not take its dose exactly as indicated, sub-therapeutic levels of ivacaftor can occur. Further, different fat content might result in relevantly different exposure to ivacaftor, there is every chance of variability of ivacaftor in blood with different food content.
The exposure of ivacaftor increased approximately 2.5-to 4-fold when given with food that contains fat. Therefore, KALYDECO tablet is administered with fat-containing food. Examples of fat-containing foods include eggs, butter, peanut butter, cheese pizza, whole-milk dairy products (such as whole milk, cheese, and yogurt), etc. KALYDECO granules (2 x 75 mg) had similar bioavailability as the 150 mg tablet when given with fat-containing food in adult subjects.
The effect of food on ivacaftor absorption is similar for KALYDECO granules and the 150 mg tablet formulation.
Clinical study during KALYDECO* product development shows clear food affect.
After oral administration of a single 150 mg dose to healthy volunteers in the fasted state, the mean (SD) for AUC0,õ and Cmax were 3620 (1840) ng*hr/mL and 218 (110) ng/mL, respectively. In the same study, oral administration of a single 150 mg dose in the fed state led to a substantial increase in exposure: AUC0,õ was 10600 (5260) ng*hr/mL and Cmax was 768 (233) ng/mL. The exposure of ivacaftor increased approximately 2- to 4-fold when given with food containing fat.
Therefore, KALYDECO is administered with fat-containing food. There is a clear effect of concomitant food intake on the speed and magnitude of absorption of ivacaftor.
In healthy volunteers high fat breakfast increased Cmax and AUC of 150 mg tablet formulation by an order of magnitude around 2- to 4 and delayed Tmax from 3 to 5 hours. A consistent effect was observed in patients with CF and pancreatic insufficiency in whom ivacaftor 275 mg oral solution was given. In this later case a standard CF meal (which contains up to 200% of the fat content of a standard meal) was compared with a fasted state. The impact of food on the PK of ivacaftor may have implications in clinical practice. Clinical studies were conducted advising patients to take ivacaftor with food containing fat. A recommendation that ivacaftor to be taken with food or shortly after a meal is included in the labeling information issued by the FDA and EMEA in respect of the KALYDECO . If a patient does not take its dose exactly as indicated, sub-therapeutic levels of ivacaftor can occur. Further, different fat content might result in relevantly different exposure to ivacaftor, there is every chance of variability of ivacaftor in blood with different food content.
3 The dissolution rate and bioavailability of known ivacaftor formulations are not optimal. A
similar bioavailability of ivacaftor formulation irrespective of the polymorphic forms of active ingredient is the need of the hour. Furthermore, the effectiveness of ivacaftor may be enhanced if it could be formulated to be taken with or without food, thus decreasing the likelihood of patient compliance problems.
A formulation that enhances the bioavailability of ivacaftor would facilitate reduction of the dosage strength with the possibility of achieving a better safety profile.
Nanoparticulate active agent compositions, first described in US5145684, are particles comprising a poorly soluble therapeutic or diagnostic agent having adsorbed onto, or associated with, the surface thereof a non-cross linked surface stabilizer.
Nanoparticulate active agent compositions and methods of making nanoparticulate active agent compositions are disclosed in US5298262, US5302401, US5336507, US5340564, US5346702, US5352459, US5429824, US5470583, US5510118, US5518187, US5534270, US5543133,US5560931, US5560932, US5565188, US5569448, US5571536, US5573783, US5580579, US5585108, US5587143, US5591456, US5622938, US5662883, US5665331, US5718388, US5834025, US5862999, US6011068, US6031003, US6211244, US6264922, US6267989, US6270806, US6313146, US6316029, US6375986, US6406718, US6428814, US6431478, US6432381, US6582285, US6592903, US6723068, US6742734, US6745962, US6811767, US6908626, 1JS6969529, US6976647, US6991191, US7198795, US7244451, US7288267, US7320802, US7390505, US7459283, US7521068, US7575184, US7695739,US7713551, US7763278, US7780989, US7825087, US7842232, US7850995, US7879360, 1JS7910577, US7927627, US7931917, US8119163, US8293277, US8779004,US9012511, USRE41884, US20030087308, US20030215502, US20040015134, US20040105778,US20040105889, US20040115134, US20040156895, US20040173696, US20040195413,US20040258757, US20050147664, US20080124393, US20080152585, US20080171091, US20080213374, US20080213378, US20080220074, US20080226734, US20080248123, US20080254114, US20080317843, US20090035366, US20090074873, US20090155331, US20090238884, US20090252807, US20090269400, US20090291142, US20090297596, US20090304801, US20100028439, US20100221327, US20100247636, US20100260858, US20100260859, US20100316725, US20110008435, US20110027371, US20110064803, W02009002427.
US4783484 discloses amorphous small particle compositions; US4826689 discloses method for making uniformly sized particles from water-insoluble organic compounds;
discloses method for making uniformly-sized particles from insoluble compounds. These are also specifically incorporated herein by reference.
None of the above references describes nanoparticulate compositions of ivacaftor or a pharmaceutically acceptable salt thereof.
The present invention relates to nanoparticulate ivacaftor compositions, such as nanoparticulate ivacaftor or a pharmaceutically acceptable salt thereof, which addresses the needs described above by providing nanoparticulate ivacaftor compositions which overcome the shortcomings of known non-nanoparticulate ivacaftor formulations.
SUMMARY OF THE INVENTION
The present invention relates to stable nanoparticulate compositions comprising ivacaftor or a pharmaceutically acceptable salt thereof. The ivacaftor nanoparticles have good stability and have an effective average particle size of less than about 2000 nm. One aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising ivacaftor or a pharmaceutically acceptable salt thereof in a crystalline form, an amorphous form, a semi-crystalline form, or mixtures thereof.
One aspect of the invention relates to a stable nanoparticulate composition comprising ivacaftor or a pharmaceutically acceptable salt thereof and at least one surface stabilizer. The nanoparticulate ivacaftor compositions of the invention may further comprise one or more pharmaceutically acceptable excipients, carriers and the like.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer.
Further, the composition comprises at least one surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and a zwitterionic surface stabilizer.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer, wherein at least one surface stabilizer is selected from the group consisting of copolymers of vinylpyrrolidone and vinyl acetate or copovidone, polyvinyl caprolactam -polyvinyl acetate -polyethylene glycol graft copolymer, docusate sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyoxyethylene sorbitan fatty acid esters, block copolymers based on ethylene oxide and propylene oxide, polyvinylpyrrolidone, deoxycholic acid sodium salt, sodium lauryl sulphate, benzalkonium chloride, lecithin, distearyl palmitate glyceryl, albumin, lysozyme, gelatin, macrogol 15 hydroxystearate, tyloxapol and polyethoxylated castor oil, cellulose derivates, dioctylsulfosuccinate, casein, dextran, gum acacia, cholesterol, tragacanth, stearic acid, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbuty1)-phenol polymer with ethylene oxide and formaldehyde, poloxamers, poloxamines, polyethylene oxide-containing fatty acid esters like Stearoyl macrogo1-32 glycerides, Lauroyl macrogo1-32 glycerides (e.g.
Gelucire) or a mixture thereof.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof, wherein the composition is formulated: (a) for administration selected from the group consisting of oral, pulmonary, intravenous, rectal, ophthalmic, colonic, parenteral, intracistemal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, tablets, sachets and capsules; (c) into a dosage form selected from the group consisting of lyophilized formulations, fast melt formulations, controlled release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination (a) (b), and (c).
One aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm, wherein the solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof are substantially free from amorphous form.
Another aspect of the invention relates a stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer, wherein the solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof are substantially free from amorphous form.
Another aspect of the invention relates a stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof and at least one surface stabilizer.
One aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof exhibits substantially similar oral bioavailability whether ivacaftor or a pharmaceutically acceptable salt thereof is in a crystalline form or an amorphous form or a semi-crystalline form, or mixtures thereof.
Another aspect of the invention relates a composition comprising nanoparticulate composition of ivacaftor is bioequivalent to the commercially available KALYDECO . This nanoparticulate composition of ivacaftor is irrespective of the form of ivacaftor in the formulation. Preferably a crystalline form of ivacaftor in form of nanoparticles present in a tablet formulation or suspension is bioequivalent to KALYDECO tablet or suspension dosage form.
One aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof shows enhanced bioavailability. Another aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof shows a reduced "food effect" as compared to non-nanoparticulate ivacaftor compositions. The compositions exhibit substantially similar oral bioavailability in fed and fasted subjects.
One aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof exhibits improved bioavailability as compared to known non-nanoparticulate ivacaftor compositions having an effective average particle size of greater than 2000 nm.
The invention also relates to compositions comprising nanoparticulate ivacaftor or a pharmaceutically acceptable salt thereof providing a method of treating or lessening the severity of a disease in a patient comprising administering to said patient one of the compositions as defined herein, and said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulinemia, Diabetes mellitus, Laron dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome, Pelizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Gerstmann-Stra ussler-Scheinker syndrome, COPD, dry-eye disease, Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD
without situs inversus and ciliary aplasia. Further, the composition also comprises at least one surface stabilizer, and optionally one or more pharmaceutically acceptable excipients, carriers, and optionally one or more active agents useful for the treatment of the said diseases.
The invention also relates to methods of making nanoparticulate ivacaftor compositions, or salt thereof. In some embodiments, the methods include contacting ivacaftor particles with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate ivacaftor composition having an effective average particle size of less than about 2000 nm. A
suitable surface stabilizer can be added to a nanoparticulate ivacaftor composition either before, during, or after particle size reduction. Any suitable means can be used to achieve nanoparticles reduce the particle size of ivacaftor, including, but not limited to, milling, microfluidization, precipitation, freeze drying, homogenization and the like.
Both the foregoing summary of the invention and the detailed description of the invention are exemplary and explanatory and are intended to provide further details of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig 1: Comparative dissolution study of ivacaftor nanosuspension, its formulations and other forms of ivacaftor.
Fig 2: Differential Scanning Calorimetry (DSC) pattern of ivacaftor granulated nanosuspension (Formulation II), ivacaftor and MCC
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a composition comprising nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof. The nanoparticles of ivacaftor or a pharmaceutically acceptable salt thereof have an effective average particle size of less than about 2000 nm. The compositions further comprise nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof, and at least one surface stabilizer, which may be adsorbed onto or otherwise associated with the surface of the drug.
As described above, one of the problems present with known non-nanoparticulate ivacaftor compositions (KALYDECO ) is that absorption of the drug (AUC) can differ by almost 2-4 fold when the drug is given under fed as compared to fasting conditions. This is highly undesirable, as it is generally recognized at least about 1/3 of all patients have poor compliance regarding consuming drugs per the labeling instructions. This means that for drugs having a wide variability in absorption when administered under fed as compared to fasting conditions, a large patient population does not receive a therapeutically desirable dosage. One aspect of the invention overcomes this problem as nanoparticulate ivacaftor compositions have minimal, if any, differences in absorption when the compositions are administered under fed as compared to fasting conditions.
Another problem with ivacaftor is low oral bioavailability of crystalline form as compared to amorphous form. Nanoparticulate ivacaftor compositions overcomes this problem as the bioavailability of nanoparticles of ivacaftor or a pharmaceutically acceptable salt thereof is substantially similar irrespective of the form of active ingredient. Ivacaftor is in crystalline form, amorphous form, semi-crystalline form, or mixtures thereof.
Nanoparticulate ivacaftor compositions result in reduced or eliminated side effects. However, in general terms reducing the amount of drug to which patients are exposed, while at the same time maintaining efficacious levels, may help to reduce adverse effects and improve the safety profile of the product. Because nanoparticulate ivacaftor compositions have a greater bioavailability, the nanoparticulate ivacaftor compositions enable the use of a smaller dosage as compared to known non-nanoparticulate ivacaftor compositions, thereby facilitating a reduction in side effects.
The present invention also includes compositions further comprising one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
The compositions can be formulated for administration via any pharmaceutically acceptable means, including but not limited to, parental injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, bioadhesive, vaginal, nasal, rectal, ocular, local (powders, ointments, or drops), buccal, intracisternal, intraperitoneal, or topical administrations, and the like. The small size of the ivacaftor particles (i.e. less than 2000 nm) makes the composition of the invention particularly advantageous for oral and parenteral formulations.
Oral administration is typically preferred, because of ease of administration and greater compliance. Oral dosage forms may be solid or liquid (e.g. syrup). Exemplary solid oral dosage forms include, but are not limited to, tablets, capsules (both hard gelatin and soft gelatin), sachets, lozenges, powders, pills, or granules, and the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
The present invention is described herein using several definitions, as set forth below and throughout the application.
As used herein, "about" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. Nanoparticulate active agents or nanoparticles of active agents as defined herein have an effective average particle size of less than about 2000 nm. By way of contrast, the term "non-nanoparticulate active agent" has an effective average particle size of greater than 2000 nm.
The term "ivacaftor", as used herein, expressly includes ivacaftor salts and encompasses different crystal forms (polymorphs), solvates, co-crystals, and hydrates. It also includes racemic or substantially optically pure forms of the foregoing. The terms "drug" or "active agent," when used herein, typically refers to ivacaftor but may, if clearly indicated by its context, refer to another drug.
The compositions of the invention comprise nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof. The ivacaftor salt may be an addition salt formed with a suitable organic or inorganic acid such as for example HC1, HBr, H2SO4, phosphoric acid, sulphamic acid, oxalic acid, lactic acid, malic acid, maleic acid, malonic acid, tartaric acid, succinic acid, fumaric acid, acetic acid, citric acid, 4-hydroxy benzoic acid, 2,5-dihydroxy benzoic acid, adipic acid, glycoli acid, decanoic acid, un-decanoic acid, cholic acid, dexo-cholic acid, mandelic acid, d-camphonic acid, benzoic acid, methansulphonic acid, ethanesulphonic acid, benzesulphonic acid, p-toluenesulphonic acid and the like These molecules can also be used as a co-former for solvates, and co-crystals of ivacaftor. . Further, U.S. patent no. 7,927,613 can be used as a reference for co-formers. The ivacaftor may be present in racemic form or as a substantially optically pure enantiomer. Different polymorphic forms, co-crystals, hydrates, solvates of ivacaftor are disclosed in various references can be used to prepare nanoparticulate composition of ivacaftor.
The present invention may be practiced with any single polymorph or a mixture thereof.
Preferably the composition comprises ivacaftor in the form of a substantially pure single polymorph, which may be amorphous form, Form A, Form B or Form C or a mixture thereof, preferably Form C. The compositions of the invention comprise nanoparticulate ivacaftor or a pharmaceutically acceptable salt thereof, in which the particles can be in a crystalline form, semi-crystalline form, amorphous form, or a combination thereof.
The term "effective average particle size," as used herein, means that at least about 50% of the nanoparticulate ivacaftor particles have a size of less than about 2000 nm (by weight or by other suitable measurement, such as by volume, number, etc.), when measured by, for example, sedimentation flow fractionation, photon correlation spectroscopy, light scattering, disk centrifugation, and other techniques known to those of skill in the art.
The term "one," "a," or "an," as used herein, is not limited to singular forms but also encompasses the plural equivalent. As used herein, the phrase "therapeutically effective amount"
shall mean that drug dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that a therapeutically effective amount of a drug that is administered to a particular subject in a particular instance will not always be effective in treating the conditions/diseases described herein, even though such dosage is deemed to be a therapeutically effective amount by those of skill in the art.
The compositions of the invention comprising nanoparticulate ivacaftor can exhibit increased bioavailability as compared to the same non-nanoparticulate ivacaftor (in other words compared to a composition wherein the ivacaftor component is present at a particle size greater than 2000 nm). Moreover, the compositions of the invention are expected to require smaller doses, and smaller tablet or other solid dosage form size as compared to prior known non-nanoparticulate formulations of the same ivacaftor to achieve the same pharmacological effect.
The increased bioavailability is significant because it means that the nanoparticulate ivacaftor dosage form will likely exhibit significantly greater drug absorption compared to the same amount of ivacaftor presented in the form of particles greater than about 2000 nm.
The invention also enables production of compositions comprising nanoparticulate ivacaftor having a desirable pharmacokinetic (PK) profile when administered to mammalian subjects.
Standard PK parameters routinely used to assess the behavior of a dosage form in vivo (in other words when administered to an animal or human subject) include Cma, (peak concentration of drug in blood plasma), Tmax (the time at which peak drug concentration is achieved) and AUC
(the area under the plasma concentration vs time curve). Methods for determining and assessing these parameters are well known in the art. The desirable pharmacokinetic profile of the compositions comprising nanoparticulate ivacaftor may comprise but is not limited to: (I) a Cmax for a nanoparticulate ivacaftor when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the C. for a non-nanoparticulate ivacaftor, administered at the same dosage; and/or (2) an AUC for nanoparticulate ivacaftor when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the AUC for a non-nanoparticulate ivacaftor, administered at the same dosage;
and/or (3) a Tmax for nanoparticulate ivacaftor when assayed in the plasma of a mammalian subject following administration, that is preferably less than the Tmax for a non-nanoparticulate formulation of the same drug administered at the same dosage. Preferably the composition exhibits a PK profile having a combination of two or more of the features (I), (2) and (3) in the preceding sentence.
The desirable pharmacokinetic profile, as used herein, is the pharmacokinetic profile measured after the initial dose.
In one embodiment, a composition comprising nanoparticulate ivacaftor exhibits, in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same drug, administered at the same dosage, a Tma, not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the Tmax exhibited by the non-nanoparticulate ivacaftor formulation.
In another embodiment, the composition comprising nanoparticulate ivacaftor exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same drug, administered at the same dosage, a Cmax which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the Cmax exhibited by the non-nanoparticulate formulation.
In yet another embodiment, the composition comprising nanoparticulate ivacaftor exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same drug, administered at the same dosage, an AUC which is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC exhibited by the non-nanoparticulate formulation.
In one embodiment of the invention, the Tmax of nanoparticulate ivacaftor when assayed in the plasma of the mammalian subject is less than about 6 hours. In other embodiments of the invention, the Tmax of the ivacaftor is less than about 5.5 hours, less than about 5 hours, less than about 4.5 hours, less than about 4 hours, less than about 3.5 hours, less than about 3 hours, less than about 2.5 hours, less than about 2 hours, less than about 1.5 hours less than about 1 hour, less than about 45 minutes, or less than about 30 minutes after administration.
In another embodiment of the invention, the compositions when tested in fasting subjects in accordance with standard pharmacokinetic practice, are proposed to produces a maximum blood plasma concentration profile in less than about 6 hours, less than about 5.5 hours, less than about hours, less than about 4.5 hours, less than about 4 hours, less than about 3.5 hours, less than about 3 hours, less than about 2.5 hours, less than about 2 hours, less than about 1.5 hours, less than about 1 hour, less than about 45 minutes, or less than about 30 minutes after the initial dose of the composition.
The desirable pharmacokinetic profile, as used herein, is the pharmacokinetic profile measured after the initial dose of nanoparticulate ivacaftor. The compositions can be formulated in any way as described herein and as known to those of skill in the art.
The invention encompasses compositions comprising nanoparticulate ivacaftor wherein the pharmacokinetic profile of the drug is not substantially affected by the fed or fasted state of a subject ingesting the composition. In other words the composition does not produce significantly different absorption levels when administered under fed as compared to fasted conditions. This means that there is no substantial difference in the quantity of drug absorbed (AUC), the rate of drug absorption (Cmax), or the length of time to Cmax(Tmax), when the nanoparticulate ivacaftor compositions are administered in the fed versus the fasted state.
The difference in absorption (AUC) or C. of the nanoparticulate ivacaftor compositions of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
The difference in Trnaõ of the nanoparticulate ivacaftor compositions of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
The invention also encompasses a composition comprising nanoparticulate ivacaftor in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
In one of the embodiment of the invention, the nanoparticulate composition of ivacaftor is bioequivalent to the commercially available KALYDECO . This nanoparticulate composition of ivacaftor is irrespective of the form of ivacaftor in the formulation.
Preferably a crystalline form of ivacaftor in form of nanoparticles present in a tablet or granules formulation is bioequivalent to KALYDECO tablet or granules dosage form.
When formulated into a solid dosage form, the compositions comprising nanoparticulate ivacaftor are proposed to have unexpectedly dramatic dissolution profiles.
Rapid dissolution of an administered active agent is preferable, as faster dissolution generally leads to greater bioavailability and faster onset of action. To improve the dissolution profile and bioavailability of ivacaftor it would be useful to increase ivacaftor dissolution so that it could attain a level close to 100% dissolution of the drug substance.
The nanoparticulate ivacaftor compositions of the invention, when formulated into a solid dosage form, preferably have a dissolution profile in which within about 5 minutes at least about 5% of the composition is dissolved. In other embodiments of the invention, at least about 10%, at least about 20%, at least about 30% or at least about 40% of the ivacaftor composition is dissolved within about 5 minutes. In yet other embodiments of the invention, preferably at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the ivacaftor composition is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the ivacaftor composition is dissolved within 20 minutes.
The compositions of the present invention provide a method of treating or lessening the severity of a disease in a patient comprising administering to said patient one of the compositions as defined herein, and said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulinemia, Diabetes mellitus, Laron dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome, Pelizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Gerstmann-Stra ussler-Scheinker syndrome, COPD, dry-eye disease, Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD
without situs inversus and ciliary aplasia. Further, the composition also comprises at least one surface stabilizer, and optionally one or more pharmaceutically acceptable excipients, carriers, and optionally one or more active agents useful for the treatment of the said diseases.
The invention provides compositions comprising nanoparticulate ivacaftor and at least one surface stabilizer. The at least one surface stabilizer is preferably adsorbed on, or otherwise associated with, the surface of the ivacaftor particles. Surface stabilizers may physically adhere on, or associate with, the surface of the ivacaftor particles, but ideally do not chemically react with the ivacaftor particles or itself Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
The present invention also includes nanoparticulate ivacaftor compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for any pharmaceutically acceptable method of administration, such as parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments or drops), buccal, intracistemal, intraperitoneal, or topical administration, and the like. A preferred route of administration is oral administration.
Accordingly, compositions of the invention may be formulated: (a) for administration selected from the group consisting of oral, pulmonary, intravenous, rectal, ophthalmic, colonic, parenteral, intracistemal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, tablets, sachets and capsules; (c) into a dosage form selected from the group consisting of lyophilized formulations, fast melt formulations, controlled release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; and (d) combinations of (a), (b), and (c).
The compositions of the invention comprise at least one surface stabilizer.
However, combinations of more than one surface stabilizer have been found to be useful and can be used in the invention. Where a plurality of surface stabilizers is used there may be a primary surface stabilizer that is present in greater concentration than the other (secondary) surface stabilizer(s).
Preferably the composition will comprise a primary surface stabilizer and at least one secondary surface stabilizer. Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients.
Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants.
Exemplary surface stabilizers include nonionic and ionic (e.g., anionic, cationic, and zwitterionic) stabilizers. Without wishing to be bound by any particular theory, it is believed that polymeric materials adhering to a particle surface can present a steric barrier preventing particle aggregation, while in the case of ionic stabilizers the stabilizing action may be attributed to electrostatic interactions.
Representative examples of surface stabilizers include albumin, including but not limited to human serum albumin and bovine albumin, hydroxypropyl methylcellulose (now known as hypromellose), hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., Tween 20 and Tween 80'1); polyethylene glycols (e.g., Carbowax 3550 and 934*), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinyl caprolactam -polyvinyl acetate -polyethylene glycol graft copolymer (Soluplus ), 4-(1,1,3,3-tetramethylbuty1)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68 and F108 , which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908 , also known as, Poloxamine 908 , which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine); Tetronic 1508 (T-1508), Tritons X-200 , which is an alkyl aryl polyether sulfonate; Crodestas F-110 , which is a mixture of sucrose stearate and sucrose distearate; p-isononylphenoxypoly-(glycidol), also known as Olin-10G or Surfactant 10-G ;
Crodestas SL-40 ); and SA9OHCO, which is C18H37CH2(CON(CH3)--CH2(CHOH)4(CH2OH)2;
decanoyl-N-methylglucamide; n-decyl 13-D-glucopyranoside; n-decyl P-D-maltopyranoside; n-dodecyl 13-D-glucopyranoside; n-dodecyl 13-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-f3-D-glucopyranoside; n-heptyl 13-D-thioglucoside; n-hexyl 13-D-glucopyranoside;
nonanoyl-N-methylglucamide; n-nonyl P-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-P-D-glucopyranoside; octyl f3-D-thioglucopyranoside; PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate, and the like.
Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate tri methyl ammonium bromide (PMM'TMAB
r), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate. Other useful cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quaternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C12-15dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride or bromide, N-alkyl (C12-18)dimethylbenzyl ammonium chloride, N- al kyl (C14-18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12-14) dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts and dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt and/or an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C12-14) dimethyl 1-naphthylmethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C12, C15, C17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, al kyl dimethyl ammoni um halogenides, tricetyl methyl ammonium chloride, de cyltrimethyl ammoni um bromide, dodecyltri ethyl ammoni um bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride (ALIQUAT
336 ), polyquaternium 10 (POLYQUAT 10 ), tetrabutyl ammonium bromide, benzyl trimethylammonium bromide, choline esters (such as choline esters of fatty acids), benzalkonium chloride, stearalkonium chloride compounds (such as stearyltrimonium chloride and Di-stearyldimonium chloride), cetyl pyridinium bromide or chloride, halide salts of quatemized polyoxyethylalkylamines, quaternized ammonium salt polymers (MIRAPOL and ALKAQUAT ), alkyl pyridinium salts; amines, such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as poly[dially1 dimethylammonium chloride]
and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar.
Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation(Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry(Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants. Organic Chemistry, (Marcel Dekker, 1990).
Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quaternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quaternary ammonium compounds.
Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quatemium-15), distearyldimonium chloride (Quaternium-5), dodecyl di methyl ethylbenzyl ammonium chlori de(Q uaterni um-14), Q uaterni um-22, Quaternium-26, Quatemium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE
(3)oley1 ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HC1, iofetamine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquatemium-1, procainehydrochloride, cocobetaine, steara1konium bentonite, stearalkoniumhectonite, stearyl trihydroxyethyl propylenedi amine dihydrofluori de, tal lowtrimoni um chloride, and h exadecyltri methyl ammonium bromide.
The following surface stabilizers may be particularly useful in the practice of the present invention copolymers of vinylpyrrolidone and vinyl acetate or copovidone (e.g., Plasdone S630, which is a random copolymer of vinyl acetate and vinyl pyrrolidone); docusate sodium (DOSS);
hydroxypropylcellulose (HPC, such as HPC-SL which has a viscosity of 2.0 to 2.9 mPas in aqueous 2% w/v solution at 20'; hydroxypropylmethylcellulose (HPMC, such as Pharmacoat 603; polysorbates or polyoxyethylene sorbitan fatty acid esters (e.g. Tween (polyoxyethylene 20 sorbitan monolaurate), Tween 40 (polyoxyethylene 20 sorbitan palmitate) or Tween 80 (polyoxyethylene 20 sorbitan monooleate)); block copolymers based on ethylene oxide and propylene oxide, also known as poloxamers (e.g., poloxamer 407 (*Lutrol F127), poloxamer 188 (Lutrol F68) or Poloxamer 338 (Lutrol F108); a polyvinylpyrrolidone (PVP), e.g. Plasdone C29/32, Plasdone C-30, Plasdone C17 and Plasdone C12;
deoxycholic acid sodium salt, sodium lauryl sulphate (SLS also known as sodium dodecyl sulphate or SDS), benzalkonium chloride (also known as alkyldimethylbenzylammonium chloride), lecithin, distearyl palmitate glyceryl or a combination thereof. Other preferred stabilizers include albumin, lysozyme, gelatin, macrogol 15 hydroxystearate (e.g. Solutol 15), tyloxapol and polyethoxylated castor oil (e.g. Cremophor EL), polyethylene oxide-containing fatty acid esters like Stearoyl macrogol-32 glycerides, Lauroyl macrogol-32 glycerides (e.g.
Gelucire ).
The surface stabilizers are commercially available and/or can be prepared by techniques known in the art. Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (R. C.
Rowe et al (ed.) 6th Edition, The Pharmaceutical Press, 2009), specifically incorporated by reference.
The preferable surface stabilizer is copolymers of vinylpyrrolidone and vinyl acetate or copovidone, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, docusate sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyoxyethylene sorbitan fatty acid esters, block copolymers based on ethylene oxide and propylene oxide, polyvinylpyrrolidone, deoxycholic acid sodium salt, sodium lauryl sulphate, benzalkonium chloride, lecithin, distearyl palmitate glyceryl, albumin, lysozyme, gelatin, macrogol 15 hydroxystearate, tyloxapol and polyethoxylated castor oil, cellulose derivates, dioctylsulfosuccinate, casein, dextran, gum acacia, cholesterol, tragacanth, stearic acid, calcium stearate, glycerol mono stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbuty1)-phenol polymer with ethylene oxide and formaldehyde, poloxamers, poloxamines, polyethylene oxide-containing fatty acid esters like Stearoyl macrogo1-32 glycerides, Lauroyl macrogo1-32 glycerides or a mixture thereof.
Pharmaceutical compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
Such excipients are known in the art. Non limiting examples of filling agents include lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents include various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel PH101 and Avicel , microcrystalline cellulose, and silicified microcrystalline cellulose;
lubricantsinclude colloidal silicon dioxide, such as Aerosil 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel; sweeteners include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame. Examples of flavoring agents are Magnasweet , bubble gum flavor, and fruit flavors, and the like;
preservatives include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride; diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel PH101 and Avicel PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose DCL21; dibasic calcium phosphate such as Emcompress ; mannitol;
starch;
sorbitol; sucrose; and glucose; disintegrants include lightly cross linked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof.
Examples of effervescent agents include effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the sodium bicarbonate component of the effervescent couple may be present.
The compositions of the invention comprise nanoparticulate ivacaftor particles having an effective average particle size of less than about 2000 nm (i.e., 2 microns), less than about 1950 nm, less than about 1900 nm, less than about 1850 nm, less than about 1800 nm, less than about 1750 nm, less than about 1700 nm, less than about 1650 nm, less than about 1600 nm, less than about 1550 nm, less than about 1500 nm, less than about 1450 nm, less than about 1400 nm, less than about 1350 nm, less than about 1300 nm, less than about 1250 nm, less than about 1200 nm, less than about 1150 nm, less than about 1100 nm, less than about 1050 nm, less than about 1000 nm, less than about 950 nm, less than about 900 nm, less than about 850 nm, less than about 800 nm, less than about 750 nm, less than about 700 nm, less than about 650 nm, less than about 600 nm, less than about 550 nm, less than about 500 nm, less than about 450 nm, less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm less than about 100, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods. Apart from the methods referred to herein, other methods suitable for measuring effective average particle size are known to a person of ordinary skill in the art.
By "an effective average particle size of less than about 2000 nm" it is meant that at least 50% of the particles have a particle size less than the effective average, by weight (or by other suitable measurement techniques, such as by volume, number, etc.), i.e., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques. In other embodiments of the invention, at least about 60%, at least about 70%, at least about 80% at least about 90%, at least about 95%, or at least about 99% of the ivacaftor particles have a particle size of less than the effective average, i.e., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
The amounts of nanoparticulate ivacaftor and one or more surface stabilizers may vary. The optimal amount of the individual components can depend, for example, upon the particular form of ivacaftor (such as the specific salt) selected, the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc.
The concentration of the ivacaftor in the nanoparticulate composition may be from about 99.5%
to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined dry weight of the ivacaftor and at least one surface stabilizer, not including other excipients.
The concentration of the ivacaftor may be present in any amount sufficient to achieve therapeutically effective levels upon administration and may vary depending on the manner in which the composition is formulated. For example, when considering ivacaftor particles dispersed in a liquid medium, the ivacaftor may typically be present in an amount from about 0.5% to about 90% by weight (salt or free base equivalent) based on the total combined weight of the drug substance, stabilizers, any added excipients and the weight of the dispersion medium.
Or, in the case of a solid dosage form the ivacaftor may typically be present in an amount from about 0.1% to about 90% by weight, preferably 0.5% to 60% by weight, and more preferably 1.0% to 40% by weight (salt or free base equivalent) based on the total combined weight of the drug substance, stabilizers, and excipients. (It will be appreciated that the calculation of a weight based concentration will depend on whether the concentration is determined as that of a particular ivacaftor salt or the free base equivalent.) Any concentration of surface stabilizer(s) which is sufficient to form stable nanoparticles of ivacaftor may be used. For example, the concentration of the at least one surface stabilizer may be present from about 0.001% to about 99.99%, from about 5.0% to about 95.0%, or from about 10% to about 90.0%, by weight, based on the total combined dry weight of the ivacaftor and at least one surface stabilizer, not including other excipients. When considering dispersed ivacaftor particles, the at least one stabilizer may typically be present in an amount from about 0.01% to about 30% by weight based on the total combined weight of the drug substance, stabilizers, any added excipients and the weight of the dispersion medium. Or, in the case of a solid dosage form the at least one stabilizer may typically be present in an amount from about 0.001% to about 90%
by weight, preferably 0.5% to 50% by weight, and more preferably 1.0% to 30%
by weight based on the total combined weight of the drug substance, stabilizers, and excipients. When more than one surface stabilizer is utilized the stabilizer present in the greatest concentration is the primary stabilizer and the other stabilizers are secondary stabilizers. For example the composition may typically comprise a primary surface stabilizer in an amount from about 0.001% to about 50% w/w (by weight of the total composition (including any dispersion medium)) and one or more secondary surface stabilizers each present in an amount, less than that of the primary stabilizer, ranging from about 0.01% to about 5% w/w (by weight of the total composition (including any dispersion medium). The combination of a primary stabilizer with one or more secondary stabilizers can be advantageous over the use of a single stabilizer. For example a plurality of stabilizers can be used to combine the steric and electrostatic stabilization effects of different types of surface stabilizer molecules.
The present invention further relates to a method of making a nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof, composition comprising contacting particles of a ivacaftor with at least one surface stabilizer for a time and under conditions sufficient to provide a composition comprising particles of ivacaftor having an effective average particle size of less than about 2000 nm.
The compositions comprising nanoparticulate ivacaftor can be made using, for example, milling or attrition (including but not limited to wet milling, dry milling and micro fluidization), homogenization, precipitation, crystal engineering, cryogenic spraying, cyclodextrin complexation, solid lipid nanoparticles (SLN), solid/liquid self-emulsifying drug delivery systems (SEDDS), freeze drying, template emulsion techniques, supercritical fluid techniques, nanoelectrospray techniques, combination thereof or and any other techniques known to those of skill in the art. Exemplary methods of making nanoparticulate compositions are described in various references mentioned above, all of which are specifically incorporated by reference.
Milling ivacaftor to obtain nanoparticulate ivacaftor dispersion comprises dispersing the particles in a liquid dispersion medium in which the ivacaftor is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the ivacaftor to the desired effective average particle size. The dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol or a mixture thereof, a preferably dispersion medium is water.
The ivacaftor particles can be reduced in size in the presence of at least one surface stabilizer.
Alternatively, nanoparticulate ivacaftor can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the ivacaftor/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
The grinding media can comprise particles that are preferably substantially spherical in shape, e.g., beads, consisting essentially of polymeric or copolymeric resin or metal like stainless steel etc. Alternatively, the grinding media can comprise a core having a coating of a polymeric or copolymeric resin adhered thereon. The grinding media preferably ranges in size from about 0.01 to about 3 mm. For fine grinding, the grinding media is preferably from about 0.02 to about 2 mm, and more preferably from about 0.03 to about 1 mm in size.
In a preferred grinding process the ivacaftor particles are made continuously.
Such a method comprises continuously introducing an ivacaftor composition according to the invention into a milling chamber, contacting the ivacaftor composition according to the invention with grinding media while in the chamber to reduce the ivacaftor particle size of the composition according to the invention, and continuously removing the nanoparticulate ivacaftor composition from the milling chamber. The grinding media is separated from the milled nanoparticulate ivacaftor composition according to the invention using known separation techniques, in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques such as centrifugation may also be employed.
Another method of forming the desired nanoparticulate ivacaftor is by microprecipitation. This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example: (1) dissolving ivacaftor in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent step (3) removal of solvent by various known methods.
The method can be followed by removal of any formed salt, if present, by dialysis or diafiltrafion and concentration of the dispersion by known means.
In homogenization method comprises dispersing ivacaftor particles in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of ivacaftor to the desired effective average particle size. The ivacaftor particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the ivacaftor particles can be contacted with one or more surface stabilizers either before or after attrition. Other compounds, such as a diluent, can be added to the ivacaftor/surface stabilizer composition either before, during, or after the ivacaftor particle size reduction process. Dispersions can be manufactured continuously or in a batch mode.
Another method of forming the desired nanoparticulate ivacaftor is by template emulsion.
Template emulsion creates nanostructured ivacaftor particles with controlled particle size distribution and rapid dissolution performance. The method comprises an oil-in-water emulsion where ivacaftor is dissolved in oil and dispersed into fine oil globules in water. The particle size distribution of ivacaftor is a direct result of the size of the emulsion droplets which can be controlled and optimized in this process. Furthermore, through selected use of solvents and stabilizers, emulsion stability is achieved with no or suppressed Ostwald ripening. Subsequently, the solvent and water are removed, and the stabilized nanostructured ivacaftor particles are recovered. Various ivacaftor particle morphologies can be achieved by appropriate control of processing conditions.
Another method of forming the desired nanoparticulate ivacaftor is by spray freezing into liquid (SFL). This technology comprises an organic or organoaqueous solution of ivacaftor with stabilizers, which is injected into a cryogenic liquid, such as liquid nitrogen. The droplets of ivacaftor solution freeze at a rate sufficient to minimize crystallization and particle growth, thus formulating nanostructured ivacaftor particles. Depending on the choice of solvent system and processing conditions, the nanoparticulate ivacaftor particles can have varying particle morphology. In the isolation step, the nitrogen and solvent are removed under conditions that avoid agglomeration or ripening of the ivacaftor particles. As a complementary technology to SFL, ultra rapid freezing (URF) may also be used to created equivalent nanostructured ivacaftor particles with greatly enhanced surface area. URF comprises an organic or organoaqueous solution of ivacaftor with stabilizers onto a cryogenic substrate.
In electrospray ionization a liquid is pushed through a very small charged, usually metal, capillary. This liquid contains the desired substance, e.g., ivacaftor, dissolved in a large amount of solvent, which is usually much more volatile than the analyte. Volatile acids, bases or buffers are often added to this solution as well. The analyte exists as an ion in solution either in a protonated form or as an anion. As like charges repel, the liquid pushes itself out of the capillary and forms a mist or an aerosol of small droplets about 10 um across. This jet of aerosol droplets is at least partially produced by a process involving the formation of a Taylor cone and a jet from the tip of this cone. A neutral carrier gas, such as nitrogen gas, is sometimes used to help nebulize the liquid and to help evaporate the neutral solvent in the small droplets. As the small droplets evaporate, suspended in the air, the charged analyte molecules are forced closer together. The drops become unstable as the similarly charged molecules come closer together and the droplets once again break up. This is referred to as Coulombic fission because it is the repulsive Coulombic forces between charged analyte molecules that drive it.
This process repeats itself until the analyte is free of solvent and is a lone ion. In nanotechnology the electrospray method may be employed to deposit single particles on surfaces, e.g., ivacaftor particles. This is accomplished by spraying colloids and ensuring that on average there is not more than one particle per droplet. Consequent drying of the surrounding solvent results in an aerosol stream of single ivacaftor particles. Here the ionizing property of the process is not crucial for the application but may be put to use in electrostatic precipitation of the particles.
Nanoparticulate ivacaftor compositions can also be made in methods utilizing supercritical fluids. In such a method ivacaftor is dissolved in a solution or vehicle which can also contain at least one surface stabilizer. The solution and a supercritical fluid are then co-introduced into a particle formation vessel. If a surface stabilizer was not previously added to the vehicle, it can be added to the particle formation vessel. The temperature and pressure are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid. Chemicals described as being useful as supercritical fluids include carbon dioxide, nitrous oxide, sulphur hexafluoride, xenon, ethylene, chlorotrifluoromethane, ethane, and trifl uoromethane.
The resultant nanoparticulate ivacaftor compositions or dispersions can be utilized in any pharmaceutically acceptable dosage form, including but not limited to injectable dosage forms, liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations. etc.
The invention also provides a method of treating a mammal in need comprising administering a stable nanoparticulate ivacaftor composition comprising: (a) particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm; and (b) at least one surface stabilizer.
The invention provides a method of increasing bioavailability (e.g., increasing the plasma levels) of ivacaftor in a subject. Such a method comprises administering to a subject, via any pharmaceutically acceptable means, an effective amount of a composition comprising nanoparticulate ivacaftor. A preferred administration method is oral administration.
The compositions of the invention may be useful in the treatment of cystic fibrosis.
The compositions of the invention comprising nanoparticulate ivacaftor can be administered to a subject via any pharmaceutically acceptable means including, but not limited to, orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracistemally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray. In some embodiments, oral administration is preferred.
As used herein, the term "subject" is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably.
Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
The compositions may also comprise adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
Solid dosage forms for oral administration include, but are not limited to, capsules (Both Hard Gelatin and Soft Gelatin), tablets, pills, powders, and granules. In such solid dosage forms, the active agent is admixed with at least one of the following: inert excipients,fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents, adsorbents, lubricants, or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the drug, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
"Therapeutically effective amount" as used herein with respect to, for example an ivacaftor dosage shall mean that dosage that provides the specific pharmacological response for which ivacaftor administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount," administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount" by those skilled in the art. It is to be further understood that ivacaftor dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
One of ordinary skill will appreciate that effective amounts of ivacaftor can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form. Actual dosage levels of ivacaftor in the nanoparticulate compositions of the invention may be varied to obtain an amount of a ivacaftor that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of ivacaftor, the desired duration of treatment, and other factors.
Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed;
the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
EXAMPLES
The following examples are provided to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples.
Example 1:
Nanoparti cul ate Iv acaftor Preparation Formulations Ingredients 1 2 3 4 5 6 7 (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) Iv acaftor 1 1 1 1 1 1 1 Soluplus 0.1 0.1 Mi cro crystall in e 0.2 cellulose Polaxomer 0.01 0.1 0.1 0.1 0.1 Povi done 0.1 0.1 Lactose 0.2 Water q. s q. s q. s q. s q. s q. s q. s Formulations Ingredients 8 9 10 11 12 13 (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) Ivacaftor 1 1 1 1 1 1 Hydroxypropyl 0.15 methylcellulose P1 asdone S-630/C-30 0.15 Docusate sodium 0.05 0.02 0.05 Gelucire 0.1 Tween 80 0.1 Pluronic 0.15 HPC-SL 0.2 0.2 Water q.s q.s q.s q.s q.s q.s A suspension of ivacaftor and a surface stabilizer and optionally excipients was prepared in distilled water and mixed well. The suspension was mixed by a High pressure Homogenizer at different speed, pressure and time. The nanoparticulate of ivacaftor can also be prepared by using ball milling apparatus. Ivacaftor formulations were processed under varied milling conditions.
All milling was performed on a ball mill apparatus using a smooth or pegged agitator. The chamber was loaded to 40-90% working volume attrition media and the remaining working volume of the chamber was filled with the mixture to be milled (the "slurry").
Each formulation was further processed using either a lyophilizing process or sprayed drying procedure to remove the milling media.
The resulting nanoparticulate ivacaftor dispersion (NCD) was examined first by microscopy and laser diffraction PSA.
In example 1, a suspension of 1.0% (w/w) of ivacaftor, 0.1% (w/w) of Polaxomer and deionised water to 100% (w/w), mixed well using a high speed homogenizer for 15 minutes and followed by nanonised with a high pressure homogenizer at 1500-2000 bar. The dispersion medium was then removed by lyophilization or spray drying. The same formulation iwa also prepared using ball milling apparatus. 1.0% (w/w) of ivacaftor, 0.1% (w/w) of Polaxomer and deionised water to 100% (w/w), was milled for 30 minutes at vibrational frequency at 3-30 Hz, in a 50 mL chamber using a smooth agitator.
The nanoparticulate dispersion of ivacaftor was then combined with various biorelevant media to determine the likely dissolution profile of the composition in vivo. Other nanoparticulate ivacaftor compositions from the examples were also prepared by using the same method as above.
Example 2:
Formulations containing nanoparticulate Ivacaftor Formulations Ingredients 14 15 16 17 18 19 20 (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) Nanoparticulate 30-80% 30-80% 30-80% 30-80% 30-80% 30-80% 30-80%
Ivacaftor Hypromellose 0-20 0-20 0-20 0-20 0-20 Polaxomer 0-25 0-25 0-25 0-25 Povidone 0-30 0-30 0-30 0-30 0-30 Microcrystalline cellulose Lactose 0-50 0-50 0-50 Sucrose 0-30 0-30 0-30 Sugar Sphere 0-50 Sodium Lauryl Sulfate Docusate Sodium 0-15 0-15 0-15 Crospovidone 0-30 0-30 0-30 0-30 0-30 0-30 0-30 Magnesium stearate The excipients were mixed with nanoparticulate of ivacaftor. and was used for compressing into tablets or capsules filling directly or granulated using various methods like dry granulation, wet granulation, melt granulation either compressed into tablets or filled into capsules or sachets.
Further, the nanoparticulate solution was sprayed onto sugar spheres in FBP or used to granulate a mixture of excipients, dried, mixed with other excipients for tablet compression or capsule filling. The nanoparticulate solution was also sprayed onto tablet cores with a combination of sugar coating and film coating. The solution was also used for spray drying/free drying and the dried nanoparticles formulated further into a solid dosage form. The nanoparticulate ivacaftor can also be used in melt extrusion and extrusion spheronization process to prepare various dosage forms like tablets, capsules or granules for sachets.
Example 3:
Ivacaftor nanoparticles using PVP K29/32 as surface stabilizer by wet media milling process:
Formulation I: Nanosuspension Ivacaftor 5g PVP k29/32 2.5g Water 600m1 To the surface stabilizer solution comprising 2.5g of PVP in 600m1 purified water, 2.5g Ivacaftor was added and homogenized forl5mins at 1200rpm for 15mins. The suspension was charged into a 0.6L stainless steel chamber of a dyno mill (KDL-A) with Zirconium beads (0.3mm) at a temperature of 20-25 C and milled to the desired particle size.
Process parameters used in the milling process are listed below:
Volume of bead: 360m1; Milling speed: 2000-4200rpm Pump rate: 40-300m1/min; Milling time: 10hrs The particle size distribution of the nanosuspension was measured by Beckman-Coulter LS13-320 as below.
Size (nanometer) Time d90 d75 (150 d25 d10 Mean 10hrs 1354 670 232 148 110 498 Day 2 1359 759 243 169 139 532 The nanosuspension formulation was further processed into granules using wet granulation process.
Formulation II: Granules of nanosuspension of ivacaftor Formulation II /ovv/w Nanosuspension Ivacaftor 10.85 PVP k29/32 5.43 Water Excipients for granulation MCC 102 78.14 PVP k2/32 4.99 SLS 0.59 The nanosuspension prepared in formulation I was added to a mixture of MCC
102, PVP and SLS, mixed well and dried. The dried granules prepared were passed through a sieve.
Formulation III: Lyophilized powder The nanosuspension was lyophilized in a LabconcoFreezone Triad freeze dryer.
Formulation IIIA: Lyophilized Ivacaftor nanosuspension Formulation IIIB: Lyophilized Ivacaftor nanosuspension with 5% sucrose The processing parameters for lyophilization of the nanosuspension were as below.
Temperature Hold Ramp rate (cr) time ( C/min) Prefreeze -75 24 Primary drying -55 12 1 -25 12 0.2 -5 8 0.2 Secondary 15 5 0.2 drying 35 10 0.2 After lyophilization, the particle size of the nanosuspension was again measured by Beckman-Coulter LS13-320 after re-suspending the dry powder with purified water. The measured particle size for the lyophilized batches IIIA and IIIB were as follows:
Size (nanometer) Nanosuspension d90 c175 dm) d25 d10 Mean Example 4:
Ivacaftor nanoparticles using HPC-LF and SLS as surface stabilizers by wet media milling process:
Formulation IV
Ivacaftor 5g HPC-LF 0.9g SLS 0.045g Water 600m1 To the surface stabilizer solution comprising 0.9g of HPC-LF and 0.045g of SLS
in 600m1 purified water, 5g of Ivacaftor was added and the suspension was homogenized for 15mins at 1200rpm. The suspension was then charged into a 0.6L stainless steel chamber of a dyno mill (KDL-A) with Zirconium beads (0.3mm) at a temperature of 20-25 C and milled.
The process parameters for wet media milling in the dyno mill were as below.
Process Parameters:
Volume of bead: 480m1 Milling speed: 2500rpm Pump rate: 300m1/min Milling time: 6hrs The particle size distribution following milling was as below.
Size (nanometer) Time d90 d75 d50 d25 d10 Mean 6hrs 2416 1858 1128 515 170 1256 Example 5:
Ivacaftor nanoparticles using HPC-LF as surface stabilizer using wet media milling process:
Formulation V
Ivacaftor lOg HPC-LF 2.5g Water 600m1 To the surface stabilizer solution comprising 2.5g of HPC-LF in 600m1 purified water, 5g of Ivacaftor was added and the suspension was homogenized for 15mins at 1200rpm.
The suspension was then charged into a 0.6L stainless steel chamber of a dyno mill (KDL-A) with Zirconium beads (0.3mm) at a temperature of 20-25 C and milled. The process parameters for wet media milling in the dyno mill were as below.
Process Parameters:
Volume of bead: 480m1 Milling speed: 3200rpm Pump rate: 300m1/min Milling time: 2hrs The particle size distribution following milling was as below.
Size (nanometer) Time d90 d75 c150 d25 d10 Mean 2hrs 3037 1866 1132 380 166 1415 Example 6 (Comparative Example):
Solid dispersion of Ivacaftor with HPMCAs:
Formulation VI
Ivacaftor 500g HPMCAs 500g Acetone 70m1 Solid dispersion of Ivacaftor with HPMCAs polymer was prepared by rotary evaporation at bath temperature 43 C and 200rpm for 30mins using acetone as the solvent. The solid dispersion was dried overnight and milled.
Example 7 (Comparative Example):
Drug Excipient mixture:
Formulation VII A (Drug Excipient Slurry) Ivacaftor 50mg PVP k29/32 25mg Water 50m1 Formulation VII B (Drug Excipient Physical mixture) Ivacaftor 50mg PVP k29/32 48mg MCC 102 360mg SLS 2.7mg Formulation VII A was prepared by simple dispersion of ivacaftor in PVP
solution. Formulation VII B was prepared by mixing ivacaftor with PVP, MCC and SLS, passed through sieve and mixed well.
Dissolution studies were performed to observe the % release from 50mg drug equivalent formulations of Ivacaftor nanoparticulate formulations I and II in comparison with that of the corresponding microcrystalline ivacaftor (30 microns), microcrystalline ivacaftor slurry (Formulation VII A), physical mixture (Formulation VII B) and amorphous dispersion (Formulation VI). The dissolution media used was a modified fasted simulated intestinal fluid (FaSSIF) wherein Lecithin and Taurocholate were replaced with 0.25% SLS in a 6.5pH
phosphate buffer solution. A USP II method at 65 rpm was used for all the dissolution studies.
The results are illustrated in Fig 1. The nanoparticulate formulations show significant enhancement of drug release compared to the amorphous and microcrystalline formulations.
The DSC of ivacaftor granulated nanosuspension (formulation II) shows melting point corresponding to that of ivacaftor form B indicating the drug is in the crystalline form in the granulated nanosuspension formulation II.
These examples are not intended to limit the claims in any respect, but rather to provide exemplary tablet formulations of ivacaftor which can be utilized in the methods of the invention.
Such exemplary tablets may also include a coating agent.
Fed/Fast Pharmacokinetics of oral nanoparticulate ivacaftor tablet and KALYDECO Tablets is determined by conducting a bio-study.
It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present inventions without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modification and variations of the invention provided they come within the scope of the appended claims and their equivalents.
similar bioavailability of ivacaftor formulation irrespective of the polymorphic forms of active ingredient is the need of the hour. Furthermore, the effectiveness of ivacaftor may be enhanced if it could be formulated to be taken with or without food, thus decreasing the likelihood of patient compliance problems.
A formulation that enhances the bioavailability of ivacaftor would facilitate reduction of the dosage strength with the possibility of achieving a better safety profile.
Nanoparticulate active agent compositions, first described in US5145684, are particles comprising a poorly soluble therapeutic or diagnostic agent having adsorbed onto, or associated with, the surface thereof a non-cross linked surface stabilizer.
Nanoparticulate active agent compositions and methods of making nanoparticulate active agent compositions are disclosed in US5298262, US5302401, US5336507, US5340564, US5346702, US5352459, US5429824, US5470583, US5510118, US5518187, US5534270, US5543133,US5560931, US5560932, US5565188, US5569448, US5571536, US5573783, US5580579, US5585108, US5587143, US5591456, US5622938, US5662883, US5665331, US5718388, US5834025, US5862999, US6011068, US6031003, US6211244, US6264922, US6267989, US6270806, US6313146, US6316029, US6375986, US6406718, US6428814, US6431478, US6432381, US6582285, US6592903, US6723068, US6742734, US6745962, US6811767, US6908626, 1JS6969529, US6976647, US6991191, US7198795, US7244451, US7288267, US7320802, US7390505, US7459283, US7521068, US7575184, US7695739,US7713551, US7763278, US7780989, US7825087, US7842232, US7850995, US7879360, 1JS7910577, US7927627, US7931917, US8119163, US8293277, US8779004,US9012511, USRE41884, US20030087308, US20030215502, US20040015134, US20040105778,US20040105889, US20040115134, US20040156895, US20040173696, US20040195413,US20040258757, US20050147664, US20080124393, US20080152585, US20080171091, US20080213374, US20080213378, US20080220074, US20080226734, US20080248123, US20080254114, US20080317843, US20090035366, US20090074873, US20090155331, US20090238884, US20090252807, US20090269400, US20090291142, US20090297596, US20090304801, US20100028439, US20100221327, US20100247636, US20100260858, US20100260859, US20100316725, US20110008435, US20110027371, US20110064803, W02009002427.
US4783484 discloses amorphous small particle compositions; US4826689 discloses method for making uniformly sized particles from water-insoluble organic compounds;
discloses method for making uniformly-sized particles from insoluble compounds. These are also specifically incorporated herein by reference.
None of the above references describes nanoparticulate compositions of ivacaftor or a pharmaceutically acceptable salt thereof.
The present invention relates to nanoparticulate ivacaftor compositions, such as nanoparticulate ivacaftor or a pharmaceutically acceptable salt thereof, which addresses the needs described above by providing nanoparticulate ivacaftor compositions which overcome the shortcomings of known non-nanoparticulate ivacaftor formulations.
SUMMARY OF THE INVENTION
The present invention relates to stable nanoparticulate compositions comprising ivacaftor or a pharmaceutically acceptable salt thereof. The ivacaftor nanoparticles have good stability and have an effective average particle size of less than about 2000 nm. One aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising ivacaftor or a pharmaceutically acceptable salt thereof in a crystalline form, an amorphous form, a semi-crystalline form, or mixtures thereof.
One aspect of the invention relates to a stable nanoparticulate composition comprising ivacaftor or a pharmaceutically acceptable salt thereof and at least one surface stabilizer. The nanoparticulate ivacaftor compositions of the invention may further comprise one or more pharmaceutically acceptable excipients, carriers and the like.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer.
Further, the composition comprises at least one surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and a zwitterionic surface stabilizer.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer, wherein at least one surface stabilizer is selected from the group consisting of copolymers of vinylpyrrolidone and vinyl acetate or copovidone, polyvinyl caprolactam -polyvinyl acetate -polyethylene glycol graft copolymer, docusate sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyoxyethylene sorbitan fatty acid esters, block copolymers based on ethylene oxide and propylene oxide, polyvinylpyrrolidone, deoxycholic acid sodium salt, sodium lauryl sulphate, benzalkonium chloride, lecithin, distearyl palmitate glyceryl, albumin, lysozyme, gelatin, macrogol 15 hydroxystearate, tyloxapol and polyethoxylated castor oil, cellulose derivates, dioctylsulfosuccinate, casein, dextran, gum acacia, cholesterol, tragacanth, stearic acid, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbuty1)-phenol polymer with ethylene oxide and formaldehyde, poloxamers, poloxamines, polyethylene oxide-containing fatty acid esters like Stearoyl macrogo1-32 glycerides, Lauroyl macrogo1-32 glycerides (e.g.
Gelucire) or a mixture thereof.
Another aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof, wherein the composition is formulated: (a) for administration selected from the group consisting of oral, pulmonary, intravenous, rectal, ophthalmic, colonic, parenteral, intracistemal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, tablets, sachets and capsules; (c) into a dosage form selected from the group consisting of lyophilized formulations, fast melt formulations, controlled release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination (a) (b), and (c).
One aspect of the invention relates to a stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm, wherein the solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof are substantially free from amorphous form.
Another aspect of the invention relates a stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer, wherein the solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof are substantially free from amorphous form.
Another aspect of the invention relates a stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof and at least one surface stabilizer.
One aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof exhibits substantially similar oral bioavailability whether ivacaftor or a pharmaceutically acceptable salt thereof is in a crystalline form or an amorphous form or a semi-crystalline form, or mixtures thereof.
Another aspect of the invention relates a composition comprising nanoparticulate composition of ivacaftor is bioequivalent to the commercially available KALYDECO . This nanoparticulate composition of ivacaftor is irrespective of the form of ivacaftor in the formulation. Preferably a crystalline form of ivacaftor in form of nanoparticles present in a tablet formulation or suspension is bioequivalent to KALYDECO tablet or suspension dosage form.
One aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof shows enhanced bioavailability. Another aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof shows a reduced "food effect" as compared to non-nanoparticulate ivacaftor compositions. The compositions exhibit substantially similar oral bioavailability in fed and fasted subjects.
One aspect of the invention relates to a composition comprising a stable nanoparticulate of ivacaftor, or a pharmaceutically acceptable salt thereof exhibits improved bioavailability as compared to known non-nanoparticulate ivacaftor compositions having an effective average particle size of greater than 2000 nm.
The invention also relates to compositions comprising nanoparticulate ivacaftor or a pharmaceutically acceptable salt thereof providing a method of treating or lessening the severity of a disease in a patient comprising administering to said patient one of the compositions as defined herein, and said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulinemia, Diabetes mellitus, Laron dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome, Pelizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Gerstmann-Stra ussler-Scheinker syndrome, COPD, dry-eye disease, Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD
without situs inversus and ciliary aplasia. Further, the composition also comprises at least one surface stabilizer, and optionally one or more pharmaceutically acceptable excipients, carriers, and optionally one or more active agents useful for the treatment of the said diseases.
The invention also relates to methods of making nanoparticulate ivacaftor compositions, or salt thereof. In some embodiments, the methods include contacting ivacaftor particles with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate ivacaftor composition having an effective average particle size of less than about 2000 nm. A
suitable surface stabilizer can be added to a nanoparticulate ivacaftor composition either before, during, or after particle size reduction. Any suitable means can be used to achieve nanoparticles reduce the particle size of ivacaftor, including, but not limited to, milling, microfluidization, precipitation, freeze drying, homogenization and the like.
Both the foregoing summary of the invention and the detailed description of the invention are exemplary and explanatory and are intended to provide further details of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig 1: Comparative dissolution study of ivacaftor nanosuspension, its formulations and other forms of ivacaftor.
Fig 2: Differential Scanning Calorimetry (DSC) pattern of ivacaftor granulated nanosuspension (Formulation II), ivacaftor and MCC
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a composition comprising nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof. The nanoparticles of ivacaftor or a pharmaceutically acceptable salt thereof have an effective average particle size of less than about 2000 nm. The compositions further comprise nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof, and at least one surface stabilizer, which may be adsorbed onto or otherwise associated with the surface of the drug.
As described above, one of the problems present with known non-nanoparticulate ivacaftor compositions (KALYDECO ) is that absorption of the drug (AUC) can differ by almost 2-4 fold when the drug is given under fed as compared to fasting conditions. This is highly undesirable, as it is generally recognized at least about 1/3 of all patients have poor compliance regarding consuming drugs per the labeling instructions. This means that for drugs having a wide variability in absorption when administered under fed as compared to fasting conditions, a large patient population does not receive a therapeutically desirable dosage. One aspect of the invention overcomes this problem as nanoparticulate ivacaftor compositions have minimal, if any, differences in absorption when the compositions are administered under fed as compared to fasting conditions.
Another problem with ivacaftor is low oral bioavailability of crystalline form as compared to amorphous form. Nanoparticulate ivacaftor compositions overcomes this problem as the bioavailability of nanoparticles of ivacaftor or a pharmaceutically acceptable salt thereof is substantially similar irrespective of the form of active ingredient. Ivacaftor is in crystalline form, amorphous form, semi-crystalline form, or mixtures thereof.
Nanoparticulate ivacaftor compositions result in reduced or eliminated side effects. However, in general terms reducing the amount of drug to which patients are exposed, while at the same time maintaining efficacious levels, may help to reduce adverse effects and improve the safety profile of the product. Because nanoparticulate ivacaftor compositions have a greater bioavailability, the nanoparticulate ivacaftor compositions enable the use of a smaller dosage as compared to known non-nanoparticulate ivacaftor compositions, thereby facilitating a reduction in side effects.
The present invention also includes compositions further comprising one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
The compositions can be formulated for administration via any pharmaceutically acceptable means, including but not limited to, parental injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, bioadhesive, vaginal, nasal, rectal, ocular, local (powders, ointments, or drops), buccal, intracisternal, intraperitoneal, or topical administrations, and the like. The small size of the ivacaftor particles (i.e. less than 2000 nm) makes the composition of the invention particularly advantageous for oral and parenteral formulations.
Oral administration is typically preferred, because of ease of administration and greater compliance. Oral dosage forms may be solid or liquid (e.g. syrup). Exemplary solid oral dosage forms include, but are not limited to, tablets, capsules (both hard gelatin and soft gelatin), sachets, lozenges, powders, pills, or granules, and the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
The present invention is described herein using several definitions, as set forth below and throughout the application.
As used herein, "about" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. Nanoparticulate active agents or nanoparticles of active agents as defined herein have an effective average particle size of less than about 2000 nm. By way of contrast, the term "non-nanoparticulate active agent" has an effective average particle size of greater than 2000 nm.
The term "ivacaftor", as used herein, expressly includes ivacaftor salts and encompasses different crystal forms (polymorphs), solvates, co-crystals, and hydrates. It also includes racemic or substantially optically pure forms of the foregoing. The terms "drug" or "active agent," when used herein, typically refers to ivacaftor but may, if clearly indicated by its context, refer to another drug.
The compositions of the invention comprise nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof. The ivacaftor salt may be an addition salt formed with a suitable organic or inorganic acid such as for example HC1, HBr, H2SO4, phosphoric acid, sulphamic acid, oxalic acid, lactic acid, malic acid, maleic acid, malonic acid, tartaric acid, succinic acid, fumaric acid, acetic acid, citric acid, 4-hydroxy benzoic acid, 2,5-dihydroxy benzoic acid, adipic acid, glycoli acid, decanoic acid, un-decanoic acid, cholic acid, dexo-cholic acid, mandelic acid, d-camphonic acid, benzoic acid, methansulphonic acid, ethanesulphonic acid, benzesulphonic acid, p-toluenesulphonic acid and the like These molecules can also be used as a co-former for solvates, and co-crystals of ivacaftor. . Further, U.S. patent no. 7,927,613 can be used as a reference for co-formers. The ivacaftor may be present in racemic form or as a substantially optically pure enantiomer. Different polymorphic forms, co-crystals, hydrates, solvates of ivacaftor are disclosed in various references can be used to prepare nanoparticulate composition of ivacaftor.
The present invention may be practiced with any single polymorph or a mixture thereof.
Preferably the composition comprises ivacaftor in the form of a substantially pure single polymorph, which may be amorphous form, Form A, Form B or Form C or a mixture thereof, preferably Form C. The compositions of the invention comprise nanoparticulate ivacaftor or a pharmaceutically acceptable salt thereof, in which the particles can be in a crystalline form, semi-crystalline form, amorphous form, or a combination thereof.
The term "effective average particle size," as used herein, means that at least about 50% of the nanoparticulate ivacaftor particles have a size of less than about 2000 nm (by weight or by other suitable measurement, such as by volume, number, etc.), when measured by, for example, sedimentation flow fractionation, photon correlation spectroscopy, light scattering, disk centrifugation, and other techniques known to those of skill in the art.
The term "one," "a," or "an," as used herein, is not limited to singular forms but also encompasses the plural equivalent. As used herein, the phrase "therapeutically effective amount"
shall mean that drug dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that a therapeutically effective amount of a drug that is administered to a particular subject in a particular instance will not always be effective in treating the conditions/diseases described herein, even though such dosage is deemed to be a therapeutically effective amount by those of skill in the art.
The compositions of the invention comprising nanoparticulate ivacaftor can exhibit increased bioavailability as compared to the same non-nanoparticulate ivacaftor (in other words compared to a composition wherein the ivacaftor component is present at a particle size greater than 2000 nm). Moreover, the compositions of the invention are expected to require smaller doses, and smaller tablet or other solid dosage form size as compared to prior known non-nanoparticulate formulations of the same ivacaftor to achieve the same pharmacological effect.
The increased bioavailability is significant because it means that the nanoparticulate ivacaftor dosage form will likely exhibit significantly greater drug absorption compared to the same amount of ivacaftor presented in the form of particles greater than about 2000 nm.
The invention also enables production of compositions comprising nanoparticulate ivacaftor having a desirable pharmacokinetic (PK) profile when administered to mammalian subjects.
Standard PK parameters routinely used to assess the behavior of a dosage form in vivo (in other words when administered to an animal or human subject) include Cma, (peak concentration of drug in blood plasma), Tmax (the time at which peak drug concentration is achieved) and AUC
(the area under the plasma concentration vs time curve). Methods for determining and assessing these parameters are well known in the art. The desirable pharmacokinetic profile of the compositions comprising nanoparticulate ivacaftor may comprise but is not limited to: (I) a Cmax for a nanoparticulate ivacaftor when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the C. for a non-nanoparticulate ivacaftor, administered at the same dosage; and/or (2) an AUC for nanoparticulate ivacaftor when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the AUC for a non-nanoparticulate ivacaftor, administered at the same dosage;
and/or (3) a Tmax for nanoparticulate ivacaftor when assayed in the plasma of a mammalian subject following administration, that is preferably less than the Tmax for a non-nanoparticulate formulation of the same drug administered at the same dosage. Preferably the composition exhibits a PK profile having a combination of two or more of the features (I), (2) and (3) in the preceding sentence.
The desirable pharmacokinetic profile, as used herein, is the pharmacokinetic profile measured after the initial dose.
In one embodiment, a composition comprising nanoparticulate ivacaftor exhibits, in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same drug, administered at the same dosage, a Tma, not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the Tmax exhibited by the non-nanoparticulate ivacaftor formulation.
In another embodiment, the composition comprising nanoparticulate ivacaftor exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same drug, administered at the same dosage, a Cmax which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the Cmax exhibited by the non-nanoparticulate formulation.
In yet another embodiment, the composition comprising nanoparticulate ivacaftor exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same drug, administered at the same dosage, an AUC which is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC exhibited by the non-nanoparticulate formulation.
In one embodiment of the invention, the Tmax of nanoparticulate ivacaftor when assayed in the plasma of the mammalian subject is less than about 6 hours. In other embodiments of the invention, the Tmax of the ivacaftor is less than about 5.5 hours, less than about 5 hours, less than about 4.5 hours, less than about 4 hours, less than about 3.5 hours, less than about 3 hours, less than about 2.5 hours, less than about 2 hours, less than about 1.5 hours less than about 1 hour, less than about 45 minutes, or less than about 30 minutes after administration.
In another embodiment of the invention, the compositions when tested in fasting subjects in accordance with standard pharmacokinetic practice, are proposed to produces a maximum blood plasma concentration profile in less than about 6 hours, less than about 5.5 hours, less than about hours, less than about 4.5 hours, less than about 4 hours, less than about 3.5 hours, less than about 3 hours, less than about 2.5 hours, less than about 2 hours, less than about 1.5 hours, less than about 1 hour, less than about 45 minutes, or less than about 30 minutes after the initial dose of the composition.
The desirable pharmacokinetic profile, as used herein, is the pharmacokinetic profile measured after the initial dose of nanoparticulate ivacaftor. The compositions can be formulated in any way as described herein and as known to those of skill in the art.
The invention encompasses compositions comprising nanoparticulate ivacaftor wherein the pharmacokinetic profile of the drug is not substantially affected by the fed or fasted state of a subject ingesting the composition. In other words the composition does not produce significantly different absorption levels when administered under fed as compared to fasted conditions. This means that there is no substantial difference in the quantity of drug absorbed (AUC), the rate of drug absorption (Cmax), or the length of time to Cmax(Tmax), when the nanoparticulate ivacaftor compositions are administered in the fed versus the fasted state.
The difference in absorption (AUC) or C. of the nanoparticulate ivacaftor compositions of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
The difference in Trnaõ of the nanoparticulate ivacaftor compositions of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
The invention also encompasses a composition comprising nanoparticulate ivacaftor in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
In one of the embodiment of the invention, the nanoparticulate composition of ivacaftor is bioequivalent to the commercially available KALYDECO . This nanoparticulate composition of ivacaftor is irrespective of the form of ivacaftor in the formulation.
Preferably a crystalline form of ivacaftor in form of nanoparticles present in a tablet or granules formulation is bioequivalent to KALYDECO tablet or granules dosage form.
When formulated into a solid dosage form, the compositions comprising nanoparticulate ivacaftor are proposed to have unexpectedly dramatic dissolution profiles.
Rapid dissolution of an administered active agent is preferable, as faster dissolution generally leads to greater bioavailability and faster onset of action. To improve the dissolution profile and bioavailability of ivacaftor it would be useful to increase ivacaftor dissolution so that it could attain a level close to 100% dissolution of the drug substance.
The nanoparticulate ivacaftor compositions of the invention, when formulated into a solid dosage form, preferably have a dissolution profile in which within about 5 minutes at least about 5% of the composition is dissolved. In other embodiments of the invention, at least about 10%, at least about 20%, at least about 30% or at least about 40% of the ivacaftor composition is dissolved within about 5 minutes. In yet other embodiments of the invention, preferably at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the ivacaftor composition is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the ivacaftor composition is dissolved within 20 minutes.
The compositions of the present invention provide a method of treating or lessening the severity of a disease in a patient comprising administering to said patient one of the compositions as defined herein, and said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulinemia, Diabetes mellitus, Laron dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome, Pelizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Gerstmann-Stra ussler-Scheinker syndrome, COPD, dry-eye disease, Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD
without situs inversus and ciliary aplasia. Further, the composition also comprises at least one surface stabilizer, and optionally one or more pharmaceutically acceptable excipients, carriers, and optionally one or more active agents useful for the treatment of the said diseases.
The invention provides compositions comprising nanoparticulate ivacaftor and at least one surface stabilizer. The at least one surface stabilizer is preferably adsorbed on, or otherwise associated with, the surface of the ivacaftor particles. Surface stabilizers may physically adhere on, or associate with, the surface of the ivacaftor particles, but ideally do not chemically react with the ivacaftor particles or itself Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
The present invention also includes nanoparticulate ivacaftor compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for any pharmaceutically acceptable method of administration, such as parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments or drops), buccal, intracistemal, intraperitoneal, or topical administration, and the like. A preferred route of administration is oral administration.
Accordingly, compositions of the invention may be formulated: (a) for administration selected from the group consisting of oral, pulmonary, intravenous, rectal, ophthalmic, colonic, parenteral, intracistemal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, tablets, sachets and capsules; (c) into a dosage form selected from the group consisting of lyophilized formulations, fast melt formulations, controlled release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; and (d) combinations of (a), (b), and (c).
The compositions of the invention comprise at least one surface stabilizer.
However, combinations of more than one surface stabilizer have been found to be useful and can be used in the invention. Where a plurality of surface stabilizers is used there may be a primary surface stabilizer that is present in greater concentration than the other (secondary) surface stabilizer(s).
Preferably the composition will comprise a primary surface stabilizer and at least one secondary surface stabilizer. Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients.
Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants.
Exemplary surface stabilizers include nonionic and ionic (e.g., anionic, cationic, and zwitterionic) stabilizers. Without wishing to be bound by any particular theory, it is believed that polymeric materials adhering to a particle surface can present a steric barrier preventing particle aggregation, while in the case of ionic stabilizers the stabilizing action may be attributed to electrostatic interactions.
Representative examples of surface stabilizers include albumin, including but not limited to human serum albumin and bovine albumin, hydroxypropyl methylcellulose (now known as hypromellose), hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., Tween 20 and Tween 80'1); polyethylene glycols (e.g., Carbowax 3550 and 934*), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinyl caprolactam -polyvinyl acetate -polyethylene glycol graft copolymer (Soluplus ), 4-(1,1,3,3-tetramethylbuty1)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68 and F108 , which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908 , also known as, Poloxamine 908 , which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine); Tetronic 1508 (T-1508), Tritons X-200 , which is an alkyl aryl polyether sulfonate; Crodestas F-110 , which is a mixture of sucrose stearate and sucrose distearate; p-isononylphenoxypoly-(glycidol), also known as Olin-10G or Surfactant 10-G ;
Crodestas SL-40 ); and SA9OHCO, which is C18H37CH2(CON(CH3)--CH2(CHOH)4(CH2OH)2;
decanoyl-N-methylglucamide; n-decyl 13-D-glucopyranoside; n-decyl P-D-maltopyranoside; n-dodecyl 13-D-glucopyranoside; n-dodecyl 13-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-f3-D-glucopyranoside; n-heptyl 13-D-thioglucoside; n-hexyl 13-D-glucopyranoside;
nonanoyl-N-methylglucamide; n-nonyl P-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-P-D-glucopyranoside; octyl f3-D-thioglucopyranoside; PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate, and the like.
Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate tri methyl ammonium bromide (PMM'TMAB
r), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate. Other useful cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quaternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C12-15dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride or bromide, N-alkyl (C12-18)dimethylbenzyl ammonium chloride, N- al kyl (C14-18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12-14) dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts and dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt and/or an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C12-14) dimethyl 1-naphthylmethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C12, C15, C17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, al kyl dimethyl ammoni um halogenides, tricetyl methyl ammonium chloride, de cyltrimethyl ammoni um bromide, dodecyltri ethyl ammoni um bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride (ALIQUAT
336 ), polyquaternium 10 (POLYQUAT 10 ), tetrabutyl ammonium bromide, benzyl trimethylammonium bromide, choline esters (such as choline esters of fatty acids), benzalkonium chloride, stearalkonium chloride compounds (such as stearyltrimonium chloride and Di-stearyldimonium chloride), cetyl pyridinium bromide or chloride, halide salts of quatemized polyoxyethylalkylamines, quaternized ammonium salt polymers (MIRAPOL and ALKAQUAT ), alkyl pyridinium salts; amines, such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as poly[dially1 dimethylammonium chloride]
and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar.
Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation(Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry(Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants. Organic Chemistry, (Marcel Dekker, 1990).
Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quaternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quaternary ammonium compounds.
Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quatemium-15), distearyldimonium chloride (Quaternium-5), dodecyl di methyl ethylbenzyl ammonium chlori de(Q uaterni um-14), Q uaterni um-22, Quaternium-26, Quatemium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE
(3)oley1 ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HC1, iofetamine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquatemium-1, procainehydrochloride, cocobetaine, steara1konium bentonite, stearalkoniumhectonite, stearyl trihydroxyethyl propylenedi amine dihydrofluori de, tal lowtrimoni um chloride, and h exadecyltri methyl ammonium bromide.
The following surface stabilizers may be particularly useful in the practice of the present invention copolymers of vinylpyrrolidone and vinyl acetate or copovidone (e.g., Plasdone S630, which is a random copolymer of vinyl acetate and vinyl pyrrolidone); docusate sodium (DOSS);
hydroxypropylcellulose (HPC, such as HPC-SL which has a viscosity of 2.0 to 2.9 mPas in aqueous 2% w/v solution at 20'; hydroxypropylmethylcellulose (HPMC, such as Pharmacoat 603; polysorbates or polyoxyethylene sorbitan fatty acid esters (e.g. Tween (polyoxyethylene 20 sorbitan monolaurate), Tween 40 (polyoxyethylene 20 sorbitan palmitate) or Tween 80 (polyoxyethylene 20 sorbitan monooleate)); block copolymers based on ethylene oxide and propylene oxide, also known as poloxamers (e.g., poloxamer 407 (*Lutrol F127), poloxamer 188 (Lutrol F68) or Poloxamer 338 (Lutrol F108); a polyvinylpyrrolidone (PVP), e.g. Plasdone C29/32, Plasdone C-30, Plasdone C17 and Plasdone C12;
deoxycholic acid sodium salt, sodium lauryl sulphate (SLS also known as sodium dodecyl sulphate or SDS), benzalkonium chloride (also known as alkyldimethylbenzylammonium chloride), lecithin, distearyl palmitate glyceryl or a combination thereof. Other preferred stabilizers include albumin, lysozyme, gelatin, macrogol 15 hydroxystearate (e.g. Solutol 15), tyloxapol and polyethoxylated castor oil (e.g. Cremophor EL), polyethylene oxide-containing fatty acid esters like Stearoyl macrogol-32 glycerides, Lauroyl macrogol-32 glycerides (e.g.
Gelucire ).
The surface stabilizers are commercially available and/or can be prepared by techniques known in the art. Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (R. C.
Rowe et al (ed.) 6th Edition, The Pharmaceutical Press, 2009), specifically incorporated by reference.
The preferable surface stabilizer is copolymers of vinylpyrrolidone and vinyl acetate or copovidone, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, docusate sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyoxyethylene sorbitan fatty acid esters, block copolymers based on ethylene oxide and propylene oxide, polyvinylpyrrolidone, deoxycholic acid sodium salt, sodium lauryl sulphate, benzalkonium chloride, lecithin, distearyl palmitate glyceryl, albumin, lysozyme, gelatin, macrogol 15 hydroxystearate, tyloxapol and polyethoxylated castor oil, cellulose derivates, dioctylsulfosuccinate, casein, dextran, gum acacia, cholesterol, tragacanth, stearic acid, calcium stearate, glycerol mono stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbuty1)-phenol polymer with ethylene oxide and formaldehyde, poloxamers, poloxamines, polyethylene oxide-containing fatty acid esters like Stearoyl macrogo1-32 glycerides, Lauroyl macrogo1-32 glycerides or a mixture thereof.
Pharmaceutical compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
Such excipients are known in the art. Non limiting examples of filling agents include lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents include various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel PH101 and Avicel , microcrystalline cellulose, and silicified microcrystalline cellulose;
lubricantsinclude colloidal silicon dioxide, such as Aerosil 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel; sweeteners include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame. Examples of flavoring agents are Magnasweet , bubble gum flavor, and fruit flavors, and the like;
preservatives include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride; diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel PH101 and Avicel PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose DCL21; dibasic calcium phosphate such as Emcompress ; mannitol;
starch;
sorbitol; sucrose; and glucose; disintegrants include lightly cross linked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof.
Examples of effervescent agents include effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the sodium bicarbonate component of the effervescent couple may be present.
The compositions of the invention comprise nanoparticulate ivacaftor particles having an effective average particle size of less than about 2000 nm (i.e., 2 microns), less than about 1950 nm, less than about 1900 nm, less than about 1850 nm, less than about 1800 nm, less than about 1750 nm, less than about 1700 nm, less than about 1650 nm, less than about 1600 nm, less than about 1550 nm, less than about 1500 nm, less than about 1450 nm, less than about 1400 nm, less than about 1350 nm, less than about 1300 nm, less than about 1250 nm, less than about 1200 nm, less than about 1150 nm, less than about 1100 nm, less than about 1050 nm, less than about 1000 nm, less than about 950 nm, less than about 900 nm, less than about 850 nm, less than about 800 nm, less than about 750 nm, less than about 700 nm, less than about 650 nm, less than about 600 nm, less than about 550 nm, less than about 500 nm, less than about 450 nm, less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm less than about 100, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods. Apart from the methods referred to herein, other methods suitable for measuring effective average particle size are known to a person of ordinary skill in the art.
By "an effective average particle size of less than about 2000 nm" it is meant that at least 50% of the particles have a particle size less than the effective average, by weight (or by other suitable measurement techniques, such as by volume, number, etc.), i.e., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques. In other embodiments of the invention, at least about 60%, at least about 70%, at least about 80% at least about 90%, at least about 95%, or at least about 99% of the ivacaftor particles have a particle size of less than the effective average, i.e., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
The amounts of nanoparticulate ivacaftor and one or more surface stabilizers may vary. The optimal amount of the individual components can depend, for example, upon the particular form of ivacaftor (such as the specific salt) selected, the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc.
The concentration of the ivacaftor in the nanoparticulate composition may be from about 99.5%
to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined dry weight of the ivacaftor and at least one surface stabilizer, not including other excipients.
The concentration of the ivacaftor may be present in any amount sufficient to achieve therapeutically effective levels upon administration and may vary depending on the manner in which the composition is formulated. For example, when considering ivacaftor particles dispersed in a liquid medium, the ivacaftor may typically be present in an amount from about 0.5% to about 90% by weight (salt or free base equivalent) based on the total combined weight of the drug substance, stabilizers, any added excipients and the weight of the dispersion medium.
Or, in the case of a solid dosage form the ivacaftor may typically be present in an amount from about 0.1% to about 90% by weight, preferably 0.5% to 60% by weight, and more preferably 1.0% to 40% by weight (salt or free base equivalent) based on the total combined weight of the drug substance, stabilizers, and excipients. (It will be appreciated that the calculation of a weight based concentration will depend on whether the concentration is determined as that of a particular ivacaftor salt or the free base equivalent.) Any concentration of surface stabilizer(s) which is sufficient to form stable nanoparticles of ivacaftor may be used. For example, the concentration of the at least one surface stabilizer may be present from about 0.001% to about 99.99%, from about 5.0% to about 95.0%, or from about 10% to about 90.0%, by weight, based on the total combined dry weight of the ivacaftor and at least one surface stabilizer, not including other excipients. When considering dispersed ivacaftor particles, the at least one stabilizer may typically be present in an amount from about 0.01% to about 30% by weight based on the total combined weight of the drug substance, stabilizers, any added excipients and the weight of the dispersion medium. Or, in the case of a solid dosage form the at least one stabilizer may typically be present in an amount from about 0.001% to about 90%
by weight, preferably 0.5% to 50% by weight, and more preferably 1.0% to 30%
by weight based on the total combined weight of the drug substance, stabilizers, and excipients. When more than one surface stabilizer is utilized the stabilizer present in the greatest concentration is the primary stabilizer and the other stabilizers are secondary stabilizers. For example the composition may typically comprise a primary surface stabilizer in an amount from about 0.001% to about 50% w/w (by weight of the total composition (including any dispersion medium)) and one or more secondary surface stabilizers each present in an amount, less than that of the primary stabilizer, ranging from about 0.01% to about 5% w/w (by weight of the total composition (including any dispersion medium). The combination of a primary stabilizer with one or more secondary stabilizers can be advantageous over the use of a single stabilizer. For example a plurality of stabilizers can be used to combine the steric and electrostatic stabilization effects of different types of surface stabilizer molecules.
The present invention further relates to a method of making a nanoparticulate ivacaftor, or a pharmaceutically acceptable salt thereof, composition comprising contacting particles of a ivacaftor with at least one surface stabilizer for a time and under conditions sufficient to provide a composition comprising particles of ivacaftor having an effective average particle size of less than about 2000 nm.
The compositions comprising nanoparticulate ivacaftor can be made using, for example, milling or attrition (including but not limited to wet milling, dry milling and micro fluidization), homogenization, precipitation, crystal engineering, cryogenic spraying, cyclodextrin complexation, solid lipid nanoparticles (SLN), solid/liquid self-emulsifying drug delivery systems (SEDDS), freeze drying, template emulsion techniques, supercritical fluid techniques, nanoelectrospray techniques, combination thereof or and any other techniques known to those of skill in the art. Exemplary methods of making nanoparticulate compositions are described in various references mentioned above, all of which are specifically incorporated by reference.
Milling ivacaftor to obtain nanoparticulate ivacaftor dispersion comprises dispersing the particles in a liquid dispersion medium in which the ivacaftor is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the ivacaftor to the desired effective average particle size. The dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol or a mixture thereof, a preferably dispersion medium is water.
The ivacaftor particles can be reduced in size in the presence of at least one surface stabilizer.
Alternatively, nanoparticulate ivacaftor can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the ivacaftor/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
The grinding media can comprise particles that are preferably substantially spherical in shape, e.g., beads, consisting essentially of polymeric or copolymeric resin or metal like stainless steel etc. Alternatively, the grinding media can comprise a core having a coating of a polymeric or copolymeric resin adhered thereon. The grinding media preferably ranges in size from about 0.01 to about 3 mm. For fine grinding, the grinding media is preferably from about 0.02 to about 2 mm, and more preferably from about 0.03 to about 1 mm in size.
In a preferred grinding process the ivacaftor particles are made continuously.
Such a method comprises continuously introducing an ivacaftor composition according to the invention into a milling chamber, contacting the ivacaftor composition according to the invention with grinding media while in the chamber to reduce the ivacaftor particle size of the composition according to the invention, and continuously removing the nanoparticulate ivacaftor composition from the milling chamber. The grinding media is separated from the milled nanoparticulate ivacaftor composition according to the invention using known separation techniques, in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques such as centrifugation may also be employed.
Another method of forming the desired nanoparticulate ivacaftor is by microprecipitation. This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example: (1) dissolving ivacaftor in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent step (3) removal of solvent by various known methods.
The method can be followed by removal of any formed salt, if present, by dialysis or diafiltrafion and concentration of the dispersion by known means.
In homogenization method comprises dispersing ivacaftor particles in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of ivacaftor to the desired effective average particle size. The ivacaftor particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the ivacaftor particles can be contacted with one or more surface stabilizers either before or after attrition. Other compounds, such as a diluent, can be added to the ivacaftor/surface stabilizer composition either before, during, or after the ivacaftor particle size reduction process. Dispersions can be manufactured continuously or in a batch mode.
Another method of forming the desired nanoparticulate ivacaftor is by template emulsion.
Template emulsion creates nanostructured ivacaftor particles with controlled particle size distribution and rapid dissolution performance. The method comprises an oil-in-water emulsion where ivacaftor is dissolved in oil and dispersed into fine oil globules in water. The particle size distribution of ivacaftor is a direct result of the size of the emulsion droplets which can be controlled and optimized in this process. Furthermore, through selected use of solvents and stabilizers, emulsion stability is achieved with no or suppressed Ostwald ripening. Subsequently, the solvent and water are removed, and the stabilized nanostructured ivacaftor particles are recovered. Various ivacaftor particle morphologies can be achieved by appropriate control of processing conditions.
Another method of forming the desired nanoparticulate ivacaftor is by spray freezing into liquid (SFL). This technology comprises an organic or organoaqueous solution of ivacaftor with stabilizers, which is injected into a cryogenic liquid, such as liquid nitrogen. The droplets of ivacaftor solution freeze at a rate sufficient to minimize crystallization and particle growth, thus formulating nanostructured ivacaftor particles. Depending on the choice of solvent system and processing conditions, the nanoparticulate ivacaftor particles can have varying particle morphology. In the isolation step, the nitrogen and solvent are removed under conditions that avoid agglomeration or ripening of the ivacaftor particles. As a complementary technology to SFL, ultra rapid freezing (URF) may also be used to created equivalent nanostructured ivacaftor particles with greatly enhanced surface area. URF comprises an organic or organoaqueous solution of ivacaftor with stabilizers onto a cryogenic substrate.
In electrospray ionization a liquid is pushed through a very small charged, usually metal, capillary. This liquid contains the desired substance, e.g., ivacaftor, dissolved in a large amount of solvent, which is usually much more volatile than the analyte. Volatile acids, bases or buffers are often added to this solution as well. The analyte exists as an ion in solution either in a protonated form or as an anion. As like charges repel, the liquid pushes itself out of the capillary and forms a mist or an aerosol of small droplets about 10 um across. This jet of aerosol droplets is at least partially produced by a process involving the formation of a Taylor cone and a jet from the tip of this cone. A neutral carrier gas, such as nitrogen gas, is sometimes used to help nebulize the liquid and to help evaporate the neutral solvent in the small droplets. As the small droplets evaporate, suspended in the air, the charged analyte molecules are forced closer together. The drops become unstable as the similarly charged molecules come closer together and the droplets once again break up. This is referred to as Coulombic fission because it is the repulsive Coulombic forces between charged analyte molecules that drive it.
This process repeats itself until the analyte is free of solvent and is a lone ion. In nanotechnology the electrospray method may be employed to deposit single particles on surfaces, e.g., ivacaftor particles. This is accomplished by spraying colloids and ensuring that on average there is not more than one particle per droplet. Consequent drying of the surrounding solvent results in an aerosol stream of single ivacaftor particles. Here the ionizing property of the process is not crucial for the application but may be put to use in electrostatic precipitation of the particles.
Nanoparticulate ivacaftor compositions can also be made in methods utilizing supercritical fluids. In such a method ivacaftor is dissolved in a solution or vehicle which can also contain at least one surface stabilizer. The solution and a supercritical fluid are then co-introduced into a particle formation vessel. If a surface stabilizer was not previously added to the vehicle, it can be added to the particle formation vessel. The temperature and pressure are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid. Chemicals described as being useful as supercritical fluids include carbon dioxide, nitrous oxide, sulphur hexafluoride, xenon, ethylene, chlorotrifluoromethane, ethane, and trifl uoromethane.
The resultant nanoparticulate ivacaftor compositions or dispersions can be utilized in any pharmaceutically acceptable dosage form, including but not limited to injectable dosage forms, liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations. etc.
The invention also provides a method of treating a mammal in need comprising administering a stable nanoparticulate ivacaftor composition comprising: (a) particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm; and (b) at least one surface stabilizer.
The invention provides a method of increasing bioavailability (e.g., increasing the plasma levels) of ivacaftor in a subject. Such a method comprises administering to a subject, via any pharmaceutically acceptable means, an effective amount of a composition comprising nanoparticulate ivacaftor. A preferred administration method is oral administration.
The compositions of the invention may be useful in the treatment of cystic fibrosis.
The compositions of the invention comprising nanoparticulate ivacaftor can be administered to a subject via any pharmaceutically acceptable means including, but not limited to, orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracistemally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray. In some embodiments, oral administration is preferred.
As used herein, the term "subject" is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably.
Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
The compositions may also comprise adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
Solid dosage forms for oral administration include, but are not limited to, capsules (Both Hard Gelatin and Soft Gelatin), tablets, pills, powders, and granules. In such solid dosage forms, the active agent is admixed with at least one of the following: inert excipients,fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents, adsorbents, lubricants, or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the drug, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
"Therapeutically effective amount" as used herein with respect to, for example an ivacaftor dosage shall mean that dosage that provides the specific pharmacological response for which ivacaftor administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount," administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount" by those skilled in the art. It is to be further understood that ivacaftor dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
One of ordinary skill will appreciate that effective amounts of ivacaftor can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form. Actual dosage levels of ivacaftor in the nanoparticulate compositions of the invention may be varied to obtain an amount of a ivacaftor that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of ivacaftor, the desired duration of treatment, and other factors.
Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed;
the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
EXAMPLES
The following examples are provided to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples.
Example 1:
Nanoparti cul ate Iv acaftor Preparation Formulations Ingredients 1 2 3 4 5 6 7 (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) Iv acaftor 1 1 1 1 1 1 1 Soluplus 0.1 0.1 Mi cro crystall in e 0.2 cellulose Polaxomer 0.01 0.1 0.1 0.1 0.1 Povi done 0.1 0.1 Lactose 0.2 Water q. s q. s q. s q. s q. s q. s q. s Formulations Ingredients 8 9 10 11 12 13 (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) Ivacaftor 1 1 1 1 1 1 Hydroxypropyl 0.15 methylcellulose P1 asdone S-630/C-30 0.15 Docusate sodium 0.05 0.02 0.05 Gelucire 0.1 Tween 80 0.1 Pluronic 0.15 HPC-SL 0.2 0.2 Water q.s q.s q.s q.s q.s q.s A suspension of ivacaftor and a surface stabilizer and optionally excipients was prepared in distilled water and mixed well. The suspension was mixed by a High pressure Homogenizer at different speed, pressure and time. The nanoparticulate of ivacaftor can also be prepared by using ball milling apparatus. Ivacaftor formulations were processed under varied milling conditions.
All milling was performed on a ball mill apparatus using a smooth or pegged agitator. The chamber was loaded to 40-90% working volume attrition media and the remaining working volume of the chamber was filled with the mixture to be milled (the "slurry").
Each formulation was further processed using either a lyophilizing process or sprayed drying procedure to remove the milling media.
The resulting nanoparticulate ivacaftor dispersion (NCD) was examined first by microscopy and laser diffraction PSA.
In example 1, a suspension of 1.0% (w/w) of ivacaftor, 0.1% (w/w) of Polaxomer and deionised water to 100% (w/w), mixed well using a high speed homogenizer for 15 minutes and followed by nanonised with a high pressure homogenizer at 1500-2000 bar. The dispersion medium was then removed by lyophilization or spray drying. The same formulation iwa also prepared using ball milling apparatus. 1.0% (w/w) of ivacaftor, 0.1% (w/w) of Polaxomer and deionised water to 100% (w/w), was milled for 30 minutes at vibrational frequency at 3-30 Hz, in a 50 mL chamber using a smooth agitator.
The nanoparticulate dispersion of ivacaftor was then combined with various biorelevant media to determine the likely dissolution profile of the composition in vivo. Other nanoparticulate ivacaftor compositions from the examples were also prepared by using the same method as above.
Example 2:
Formulations containing nanoparticulate Ivacaftor Formulations Ingredients 14 15 16 17 18 19 20 (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) (%w/w) Nanoparticulate 30-80% 30-80% 30-80% 30-80% 30-80% 30-80% 30-80%
Ivacaftor Hypromellose 0-20 0-20 0-20 0-20 0-20 Polaxomer 0-25 0-25 0-25 0-25 Povidone 0-30 0-30 0-30 0-30 0-30 Microcrystalline cellulose Lactose 0-50 0-50 0-50 Sucrose 0-30 0-30 0-30 Sugar Sphere 0-50 Sodium Lauryl Sulfate Docusate Sodium 0-15 0-15 0-15 Crospovidone 0-30 0-30 0-30 0-30 0-30 0-30 0-30 Magnesium stearate The excipients were mixed with nanoparticulate of ivacaftor. and was used for compressing into tablets or capsules filling directly or granulated using various methods like dry granulation, wet granulation, melt granulation either compressed into tablets or filled into capsules or sachets.
Further, the nanoparticulate solution was sprayed onto sugar spheres in FBP or used to granulate a mixture of excipients, dried, mixed with other excipients for tablet compression or capsule filling. The nanoparticulate solution was also sprayed onto tablet cores with a combination of sugar coating and film coating. The solution was also used for spray drying/free drying and the dried nanoparticles formulated further into a solid dosage form. The nanoparticulate ivacaftor can also be used in melt extrusion and extrusion spheronization process to prepare various dosage forms like tablets, capsules or granules for sachets.
Example 3:
Ivacaftor nanoparticles using PVP K29/32 as surface stabilizer by wet media milling process:
Formulation I: Nanosuspension Ivacaftor 5g PVP k29/32 2.5g Water 600m1 To the surface stabilizer solution comprising 2.5g of PVP in 600m1 purified water, 2.5g Ivacaftor was added and homogenized forl5mins at 1200rpm for 15mins. The suspension was charged into a 0.6L stainless steel chamber of a dyno mill (KDL-A) with Zirconium beads (0.3mm) at a temperature of 20-25 C and milled to the desired particle size.
Process parameters used in the milling process are listed below:
Volume of bead: 360m1; Milling speed: 2000-4200rpm Pump rate: 40-300m1/min; Milling time: 10hrs The particle size distribution of the nanosuspension was measured by Beckman-Coulter LS13-320 as below.
Size (nanometer) Time d90 d75 (150 d25 d10 Mean 10hrs 1354 670 232 148 110 498 Day 2 1359 759 243 169 139 532 The nanosuspension formulation was further processed into granules using wet granulation process.
Formulation II: Granules of nanosuspension of ivacaftor Formulation II /ovv/w Nanosuspension Ivacaftor 10.85 PVP k29/32 5.43 Water Excipients for granulation MCC 102 78.14 PVP k2/32 4.99 SLS 0.59 The nanosuspension prepared in formulation I was added to a mixture of MCC
102, PVP and SLS, mixed well and dried. The dried granules prepared were passed through a sieve.
Formulation III: Lyophilized powder The nanosuspension was lyophilized in a LabconcoFreezone Triad freeze dryer.
Formulation IIIA: Lyophilized Ivacaftor nanosuspension Formulation IIIB: Lyophilized Ivacaftor nanosuspension with 5% sucrose The processing parameters for lyophilization of the nanosuspension were as below.
Temperature Hold Ramp rate (cr) time ( C/min) Prefreeze -75 24 Primary drying -55 12 1 -25 12 0.2 -5 8 0.2 Secondary 15 5 0.2 drying 35 10 0.2 After lyophilization, the particle size of the nanosuspension was again measured by Beckman-Coulter LS13-320 after re-suspending the dry powder with purified water. The measured particle size for the lyophilized batches IIIA and IIIB were as follows:
Size (nanometer) Nanosuspension d90 c175 dm) d25 d10 Mean Example 4:
Ivacaftor nanoparticles using HPC-LF and SLS as surface stabilizers by wet media milling process:
Formulation IV
Ivacaftor 5g HPC-LF 0.9g SLS 0.045g Water 600m1 To the surface stabilizer solution comprising 0.9g of HPC-LF and 0.045g of SLS
in 600m1 purified water, 5g of Ivacaftor was added and the suspension was homogenized for 15mins at 1200rpm. The suspension was then charged into a 0.6L stainless steel chamber of a dyno mill (KDL-A) with Zirconium beads (0.3mm) at a temperature of 20-25 C and milled.
The process parameters for wet media milling in the dyno mill were as below.
Process Parameters:
Volume of bead: 480m1 Milling speed: 2500rpm Pump rate: 300m1/min Milling time: 6hrs The particle size distribution following milling was as below.
Size (nanometer) Time d90 d75 d50 d25 d10 Mean 6hrs 2416 1858 1128 515 170 1256 Example 5:
Ivacaftor nanoparticles using HPC-LF as surface stabilizer using wet media milling process:
Formulation V
Ivacaftor lOg HPC-LF 2.5g Water 600m1 To the surface stabilizer solution comprising 2.5g of HPC-LF in 600m1 purified water, 5g of Ivacaftor was added and the suspension was homogenized for 15mins at 1200rpm.
The suspension was then charged into a 0.6L stainless steel chamber of a dyno mill (KDL-A) with Zirconium beads (0.3mm) at a temperature of 20-25 C and milled. The process parameters for wet media milling in the dyno mill were as below.
Process Parameters:
Volume of bead: 480m1 Milling speed: 3200rpm Pump rate: 300m1/min Milling time: 2hrs The particle size distribution following milling was as below.
Size (nanometer) Time d90 d75 c150 d25 d10 Mean 2hrs 3037 1866 1132 380 166 1415 Example 6 (Comparative Example):
Solid dispersion of Ivacaftor with HPMCAs:
Formulation VI
Ivacaftor 500g HPMCAs 500g Acetone 70m1 Solid dispersion of Ivacaftor with HPMCAs polymer was prepared by rotary evaporation at bath temperature 43 C and 200rpm for 30mins using acetone as the solvent. The solid dispersion was dried overnight and milled.
Example 7 (Comparative Example):
Drug Excipient mixture:
Formulation VII A (Drug Excipient Slurry) Ivacaftor 50mg PVP k29/32 25mg Water 50m1 Formulation VII B (Drug Excipient Physical mixture) Ivacaftor 50mg PVP k29/32 48mg MCC 102 360mg SLS 2.7mg Formulation VII A was prepared by simple dispersion of ivacaftor in PVP
solution. Formulation VII B was prepared by mixing ivacaftor with PVP, MCC and SLS, passed through sieve and mixed well.
Dissolution studies were performed to observe the % release from 50mg drug equivalent formulations of Ivacaftor nanoparticulate formulations I and II in comparison with that of the corresponding microcrystalline ivacaftor (30 microns), microcrystalline ivacaftor slurry (Formulation VII A), physical mixture (Formulation VII B) and amorphous dispersion (Formulation VI). The dissolution media used was a modified fasted simulated intestinal fluid (FaSSIF) wherein Lecithin and Taurocholate were replaced with 0.25% SLS in a 6.5pH
phosphate buffer solution. A USP II method at 65 rpm was used for all the dissolution studies.
The results are illustrated in Fig 1. The nanoparticulate formulations show significant enhancement of drug release compared to the amorphous and microcrystalline formulations.
The DSC of ivacaftor granulated nanosuspension (formulation II) shows melting point corresponding to that of ivacaftor form B indicating the drug is in the crystalline form in the granulated nanosuspension formulation II.
These examples are not intended to limit the claims in any respect, but rather to provide exemplary tablet formulations of ivacaftor which can be utilized in the methods of the invention.
Such exemplary tablets may also include a coating agent.
Fed/Fast Pharmacokinetics of oral nanoparticulate ivacaftor tablet and KALYDECO Tablets is determined by conducting a bio-study.
It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present inventions without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modification and variations of the invention provided they come within the scope of the appended claims and their equivalents.
Claims (10)
1. A stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm.
2. The stable nanoparticulate ivacaftor composition of claim 1, wherein ivacaftor or a pharmaceutically acceptable salt thereof is in crystalline form.
3. A stable nanoparticulate ivacaftor composition comprising solid particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer.
4. The stable nanoparticulate ivacaftor composition of claim 3, wherein ivacaftor or a pharmaceutically acceptable salt thereof is in crystalline form.
5. The composition of claim 1, wherein the composition is formulated: (a) for administration selected from the group consisting of oral, pulmonary, intravenous, rectal, ophthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, soft gelatin capsules, gels, aerosols, ointments, creams, tablets, sachets and capsules; (c) into a dosage form selected from the group consisting of lyophilized formulations, fast melt formulations, controlled release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination (a) (b), and (c).
6. The composition of claim 3, wherein at least one surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and a zwitterionic surface stabilizer.
7. The composition of claim 3, wherein at least one surface stabilizer is selected from the group consisting of copolymers of vinylpyrrolidone and vinyl acetate or copovidone, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, docusate sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyoxyethylene sorbitan fatty acid esters, block copolymers based on ethylene oxide and propylene oxide, polyvinylpyrrolidone, deoxycholic acid sodium salt, sodium lauryl sulphate, benzalkonium chloride, lecithin, distearyl palmitate glyceryl, albumin, lysozyme, gelatin, macrogol 15 hydroxystearate, tyloxapol and polyethoxylated castor oil, cellulose derivates, dioctylsulfosuccinate, casein, dextran, gum acacia, cholesterol, tragacanth, stearic acid, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers, poloxamines polyethylene oxide-containing fatty acid esters like Stearoyl macrogol-32 glycerides, Lauroyl macrogol-32 glycerides or a mixture thereof.
8. A stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm, wherein the solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof are substantially free from amorphous form.
9. A stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof having an effective average particle size of less than about 2000 nm and at least one surface stabilizer, wherein the solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof are substantially free from amorphous form.
10. A stable nanoparticulate ivacaftor composition comprising solid crystalline particles of ivacaftor or a pharmaceutically acceptable salt thereof and at least one surface stabilizer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2936/CHE/2015 | 2015-06-11 | ||
IN2936CH2015 | 2015-06-11 | ||
PCT/IB2016/053433 WO2016199085A1 (en) | 2015-06-11 | 2016-06-10 | Nanoparticulate ivacaftor formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3021752A1 true CA3021752A1 (en) | 2016-12-15 |
Family
ID=57503253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3021752A Abandoned CA3021752A1 (en) | 2015-06-11 | 2016-06-10 | Nanoparticulate ivacaftor formulations |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3021752A1 (en) |
WO (1) | WO2016199085A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925863A (en) * | 2020-06-29 | 2022-01-14 | 四川大学华西医院 | Application of Ivacaftor in preparation of medicine for inhibiting novel coronavirus SARS-CoV2 |
EP4335434A1 (en) * | 2022-08-17 | 2024-03-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising ivacaftor |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
CN101006076B (en) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Modulators of ATP-binding cassette transporters |
JP5409010B2 (en) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Solid form of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
MX2014010253A (en) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Pharmaceutical composition and administration thereof. |
HUP1600270A2 (en) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US11384054B2 (en) | 2020-10-22 | 2022-07-12 | Scinopharm Taiwan, Ltd. | Crystalline form of ivacaftor and a process for preparing the same |
EP4299053A1 (en) * | 2022-06-28 | 2024-01-03 | Vysoká skola chemicko-technologická v Praze | Method for preparing an aqueous nanosuspension containing nanocrystals of pharmaceutically active ingredient and a combination of stabilizers, aqueous nanosuspension and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014010253A (en) * | 2012-02-27 | 2014-11-12 | Vertex Pharma | Pharmaceutical composition and administration thereof. |
US8674108B2 (en) * | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
-
2016
- 2016-06-10 CA CA3021752A patent/CA3021752A1/en not_active Abandoned
- 2016-06-10 WO PCT/IB2016/053433 patent/WO2016199085A1/en active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925863A (en) * | 2020-06-29 | 2022-01-14 | 四川大学华西医院 | Application of Ivacaftor in preparation of medicine for inhibiting novel coronavirus SARS-CoV2 |
CN113925863B (en) * | 2020-06-29 | 2023-01-31 | 四川大学华西医院 | Application of Ivacaftor in preparation of medicine for inhibiting novel coronavirus SARS-CoV2 |
EP4335434A1 (en) * | 2022-08-17 | 2024-03-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising ivacaftor |
Also Published As
Publication number | Publication date |
---|---|
WO2016199085A1 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3021752A1 (en) | Nanoparticulate ivacaftor formulations | |
US9012511B2 (en) | Nanoparticulate cinacalcet compositions | |
AU2006309295B2 (en) | Nanoparticulate acetaminophen formulations | |
US20070148100A1 (en) | Nanoparticulate aripiprazole formulations | |
US20070281011A1 (en) | Nanoparticulate posaconazole formulations | |
US20080213374A1 (en) | Nanoparticulate sorafenib formulations | |
JP2009518300A (en) | Mometasone composition and methods for making and using the same | |
KR20080016952A (en) | Nanoparticulate clopidogrel and aspirin combination formulations | |
US20090291142A1 (en) | Nanoparticulate bicalutamide formulations | |
JP2011514360A (en) | Nanoparticle composition of angiogenesis inhibitors | |
JP2023062070A (en) | Nanoparticles of indirubin, derivatives thereof and methods of making and using the same | |
EP1898882B1 (en) | Nanoparticulate ebastine formulations | |
US20090297596A1 (en) | Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor | |
US20100221327A1 (en) | Nanoparticulate azelnidipine formulations | |
CA2654909A1 (en) | Nanoparticulate kinase inhibitor formulations | |
MX2007015304A (en) | Nanoparticulate acetaminophen formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20220902 |
|
FZDE | Discontinued |
Effective date: 20220902 |